Michael Sela Professor Michael Sela
The W. Garfield Weston Professor of Immunology

 Complete List of Publications:

 Scientific Articles  Review Articles, Books, Lectures
 Patents  Abstracts, Book Reviews

 Scientific Articles

  1. Titration of N-carboxy-a-amino acid anhydrides in nonaqueous solvents. A. Berger, M. Sela and E. Katchalski, Anal. Chem. 25, 1554 (1953).
  2. The synthesis and spectrophotometric study of poly-L-tyrosine and poly-3,5-diiodotyrosine. E. Katchalski and M. Sela, J. Am. Chem. Soc. 75, 5284 (1953).
  3. The mechanism of polymerization of N-carboxy-a-amino acid anhydrides. M. Sela and A. Berger, J. Am. Chem. Soc. 75, 6350 (1953).
  4. Poly-p-amino-DL-phenylalanine. M. Sela and E. Katchalski, J. Am. Chem. Soc. 76, 129 (1954).
  5. Polytryptophan. A. Patchornik, M. Sela and E. Katchalski, J. Am. Chem. Soc. 76, 229 (1954).
  6. Copolymerization of a-amino acids with omega-aminohendecanoic acid. E. Katchalski, M. Sela and R. Spanier, B. Res. Counc. Israel 3, 446 (1954).
  7. Poly-a-amino acid derivatives of proteins and peptides. M. Sela B. Res. Counc. Israel 4, 109 (1954).
  8. Decarbobenzoxylation by lithium bromide. E. Katchalski, M. Sela and A. Vesely, B. Res. Counc. Israel 4, 112 (1954).
  9. The terminal groups of poly-a-amino acids. M. Sela and A. Berger, J. Am. Chem. Soc. 77, 1893 (1955).
  10. Azo derivatives of some aromatic poly-a-amino acids. M. Sela and E. Katchalski, J. Am. Chem. Soc. 77, 3662 (1955).
  11. Molecular weight distribution of linear and multichain polyamino acids. A statistical analysis. E. Katchalski, M. Gehatia and M. Sela, J. Am. Chem. Soc. 77, 6175 (1955).
  12. Multichain polyamino acids. M. Sela, E. Katchalski and M. Gehatia, J. Am. Chem. Soc. 78, 746 (1956).
  13. Spectrophotometric titration of a-amino acid copolymers containing tyrosine. M. Sela and E. Katchalski, J. Am. Chem. Soc. 78, 3986 (1956).
  14. Anaphylactic shock in guinea pigs sensitized to polytyrosyl gelatin. M. Sela, E. Katchalski and A.L. Olitzki,< Science 123, 1129 (1956).
  15. Appearance of serine upon alkaline incubation of iodinated polytyrosine. M. Sela and S. Sarid, Nature 178, 540 (1956).
  16. A method for the specific proteolytic cleavage of protein chains. C.B. Anfinsen, M. Sela and H. Tritch, Arch. Biochem. Biophys. 65, 156 (1956).
  17. Reductive cleavage of disulfide bridges in ribonuclease. M. Sela, F.H. White, Jr., and C.B. Anfinsen, Science 125, 691 (1957).
  18. Some spectrophotometric and polarimetric experiments with ribonuclease.< M. Sela and C.B. Anfinsen, Biochim. Biophys. Acta 24, 229 (1957).
  19. The correlation of ribonuclease activity with specific aspects of tertiary structure. M. Sela, C.B. Anfinsen and W.F. Harrington, Biochim. Biophys. Acta 26, 502 (1957).
  20. Studies on the structure of poly-L-proline in solution. W.F. Harrington and M. Sela, Biochim. Biophys. Acta 27, 24 (1958).
  21. Serological properties of poly-L-tyrosine. M. Sela and F. Haurowitz, Experientia 14, 91 (1958).
  22. The reductive cleavage of disulfide bonds and its application to problems of protein structure. M. Sela, F.H. White, Jr. and C.B. Anfinsen, Biochim. Biophys. Acta 31, 417 (1959).
  23. A comparison of the physical chemical properties of oxidized and reduced alkylated ribonuclease. W.F. Harrington and M. Sela, Biochim. Biophys. Acta 31, 427 (1959).
  24. An assay of pepsin using ribonuclease as substrate. A. Berger, H. Neumann and M. Sela, Biochim. Biophys. Acta 33, 249 (1959).
  25. On the reformation of disulfide bridges in proteins. M. Sela and S. Lifson, Biochim. Biophys. Acta 36, 471 (1959).
  26. Reaction of polyamino acids and proteins with thiocyanate. F. Haurowitz, J. Turner and M. Sela, Fed. Proc. 18, 244 (1959).
  27. Studies on the chemical basis of the antigenicity of proteins. 1. Antigenicity of polypeptidyl gelatins. M. Sela and R. Arnon, Biochem. J. 75, 91 (1960).
  28. Studies on the chemical basis of the antigenicity of proteins. 2. Antigenic specificity of polytyrosyl gelatins. R. Arnon and M. Sela, Biochem. J. 75, 103 (1960).
  29. Poly-L-cyclohexylalanine and poly-L-cyclohexylalanyl proteins. M. Sela and R. Arnon,
    J. Am. Chem. Soc. 82, 2625 (1960).
  30. Configurational changes of poly-L-proline in solution. I.Z. Steinberg, W.F. Harrington, A. Berger, M. Sela and E. Katchalski, J. Am. Chem. Soc. 82, 5263 (1960).
  31. Isolation of antibodies to gelatin from antigen-antibody complex by proteolysis. R. Arnon and M. Sela, Science 132, 86 (1960).
  32. Specific synthetic polypeptide antigen. M. Sela and R. Arnon, Biochim. Biophys. Acta 40, 382 (1960).
  33. Proteolytic activity in the egg white. H. Neumann and M. Sela, B. Res. Counc. Israel 9A, 103 (1960).
  34. Studies on the chemical basis of antigenicity of proteins. 3. Role of rigidity in the antigenicity of polypeptidyl gelatins. M. Sela and R. Arnon, Biochem. J. 77, 394 (1960).
  35. Optical rotatory dispersion and viscosity changes accompanying the forward and reverse mutarotation of poly-L-proline in solution. I.Z. Steinberg, M. Sela, W.F. Harrington, A. Berger and E. Katchalski, B. Res. Counc. Israel   9A, 130 (1960).
  36. The effect of urea and guanidine hydrochloride on activity and optical rotation of penicillinase. N. Citri, N. Garber and M. Sela, J. Biol. Chem. 235, 3454 (1960).
  37. Immunological properties of urinary preparations of human menopausal gonadotropins with special reference to pergonal. B. Lunenfeld, D. Givol and M. Sela, J. Clin. Endocrinol. Metabolism 21, 478 (1961).
  38. Optical rotatory properties of poly-L-tryptophan. M. Sela, I.Z. Steinberg and E. Daniel, Biochim. Biophys. Acta 46, 433 (1961).
  39. Evaluation of multichain polyglutamic acid as a possible plasma expander. W.Y. Loebl, T.D. Ullmann, A. Yaron, M. Sela, A. Berger and E. Katchalski, Proc. Soc. Exp. Biol. Med. 108, 661 (1961).
  40. The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain. C.B. Anfinsen, E. Haber, M. Sela and F.H. White, Jr., Proc. Natl. Acad. Sci. U.S. 47, 1309 (1961).
  41. Inhibition of ribonuclease by copolymers of glutamic acid and aromatic amino acids. M. Sela, J. Biol. Chem. 237, 418 (1962).
  42. The reversible reduction of disulfide bonds in polyalanyl ribonuclease. C.B. Anfinsen, M. Sela and J.P. Cooke, J. Biol. Chem. 237, 1825 (1962).
  43. Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine. M. Sela, S. Fuchs and R. Arnon, Biochem. J. 85, 223 (1962).
  44. Isolation of antibodies to antigens of low molecular weight. D. Givol, S. Fuchs and M. Sela, Biochim. Biophys. Acta  63, 222 (1962).
  45. Co-operative effects of functional groups in peptides. I. Aspartyl-serine derivatives. S.A. Bernhard, A. Berger, J.H. Carter, E. Katchalski, M. Sela and Y. Shalitin, J. Am. Chem. Soc. 84, 2421 (1962).
  46. Water-soluble polypeptidyl gliadins. M. Sela, N. Lupu, A. Yaron and A. Berger, Biochim. Biophys. Acta  62, 594 (1962).
  47. The properties of polyalanyl trypsin and polyalanyl chymotrypsin. C.J. Epstein, C.B. Anfinsen and M. Sela, J. Biol. Chem. 237, 3458 (1962).
  48. An ultracentrifugal study of the efficiency of some macromolecular inhibitors of ribonuclease. U.Z. Littauer and M. Sela, Biochim. Biophys. Acta  61, 609 (1962).
  49. Enzymatic activity of polyalanyl ribonuclease. D. Wellner, H.I. Silman and M. Sela, J. Biol. Chem. 238, 1324 (1963).
  50. Studies on the chemical basis of the antigenicity of proteins. 6. Antigenic specificity of some synthetic polypeptides containing tyrosine. S. Fuchs and M. Sela, Biochem. J. 87, 70 (1963).
  51. The effect of urea and guanidine on the helix content of poly-N5-(3-hydroxypropyl)-L-glutamine in aqueous solvent systems. A. Yaron, N. Lupu, M. Sela and A. Berger, Biochim. Biophys. Acta  69, 430 (1963).
  52. Inhibition of lysozyme by some copolymers of amino acids. M. Sela and L.A. Steiner Biochemistry 2, 410 (1963).
  53. Specific immunological unresponsiveness towards synthetic polypeptide antigens. M. Sela, S. Fuchs and M. Feldman, Science 139, 342 (1963).
  54. Hypersensitivity to a synthetic polypeptide: Induction of a delayed reaction. S. Ben-Efraim, S. Fuchs and M. Sela, Science 139, 1222 (1963).
  55. The identification of unreactive amino groups in ribonuclease and their significance to enzymatic activity. J.P. Cooke, C.B. Anfinsen and M. Sela, J. Biol. Chem. 238, 2034 (1963).
  56. Use of antibody bound to modified cellulose as an immunospecific adsorbent of antigens. A.T. Jagendorf, A. Patchornik and M. Sela, Biochim. Biophys. Acta  78, 516 (1963).
  57. Studies on the antigenic structure of ribonuclease. IV. Polyalanyl ribonuclease. R.K. Brown, M.A. Trzpis, M. Sela and C.B. Anfinsen, J. Biol. Chem. 238, 3876 (1963).
  58. A synthetic polypeptide antigen devoid of charge. M. Sela and S. Fuchs, Biochim. Biophys. Acta  74, 796 (1963).
  59. Resolution of rabbit g-globulin into two fractions by chromatography on diethylaminoethyl-Sephadex. M. Sela, D. Givol and E. Mozes, Biochim. Biophys. Acta  78, 649 (1963).
  60. Synthesis of poly-L-lysine and poly-L-lysyl albumin via e,N-trifluoroacetyl-a,N-carboxy-L-lysine anhydride. M. Sela, R. Arnon and I. Jacobson, Biopolymers 1, 517 (1963).
  61. Passive cutaneous anaphylaxis in the guinea pig with rabbit antibodies against synthetic polypeptides. S. Ben-Efraim, S. Fuchs and M. Sela, Immunology 7, 142 (1964).
  62. Isolation and fragmentation of antibodies to polytyrosyl gelatin. D. Givol and M. Sela, Biochemistry 3, 444 (1964).
  63. A comparison of fragments of rabbit antibodies and normal g-globulin by the peptide map technique. D. Givol and M. Sela, Biochemistry 3, 451 (1964).
  64. Interaction of phosphorothioate with the disulfide bonds of ribonuclease and lysozyme. H. Neumann, R.F. Goldberger and M. Sela, J. Biol. Chem. 239, 1536 (1964).
  65. Inhibition of trypsin by copolymer of glutamic acid and other amino acids. M. Rigbi and M. Sela, Biochemistry 3, 629 (1964).
  66. Uridine-specific antibodies obtained with synthetic antigens. M. Sela, H. Ungar-Waron and Y. Shechter, Proc. Natl. Acad. Sci. U.S. 52, 285 (1964).
  67. Induction of immunological tolerance towards a peptide determinant with a non-immunogenic polypeptide. I. Schechter, S. Bauminger and M. Sela, Biochim. Biophys. Acta  93, 686 (1964).
  68. Antigenicity of some new synthetic polypeptides and polypeptidyl gelatins. S. Fuchs and M. Sela, Biochem. J. 93, 566 (1964).
  69. Hydrogen ion titration of rabbit g-globulin and some of its subunits. J.K. Weltman and M. Sela, Biochim. Biophys. Acta  93, 553 (1964).
  70. Immune response to polypeptidyl proteins in rabbits tolerant to the protein carriers. I. Schechter, S. Bauminger, M. Sela, D. Nachtigal and M. Feldman, Immunochemistry 1, 249 (1964).
  71. On the role of charge and optical configuration in antigenicity. M. Sela and S. Fuchs, Proc. Symp. on Molecular and Cellular Basis of Antibody Formation, Prague, Publishing House of the Czechoslovak Academy of Sciences, p. 43 (1965).
  72. Polylysine-specific antibodies and their reaction with oligolysines. R. Arnon, M. Sela, A. Yaron and H.A. Sober, Biochemistry 4, 948 (1965).
  73. Relation between optical configuration and immunogenicity of synthetic polypeptides. F. Borek, Y. Stupp, S. Fuchs and M. Sela, Biochem. J. 96, 577 (1965).
  74. Immunospecific and non-specific fixation of complement by poly-L-lysine. R. Arnon, H. Levinhar and M. Sela, Israel J. Med. Sci. 1, 404 (1965).
  75. Conformational changes in the nonionizable water soluble synthetic polypeptide poly-N5-(3-hydroxypropyl)-L-glutamine. N. Lupu-Lotan, A. Berger and M. Sela, Biopolymers 3, 625 (1965).
  76. Preparation and characterization of poly-DL-alanyl rabbit g-globulin. S. Fuchs and M. Sela, J. Biol. Chem. 240, 3558 (1965).
  77. Active fragments obtained by cleavage of rabbit antibody with cyanogen bromide. H.J. Cahnmann, R. Arnon and M. Sela, J. Biol. Chem. 240, PC2762 (1965).
  78. Combining sites of antibodies to L-alanine and D-alanine peptide determinants. I. Schechter and M. Sela, Biochim. Biophys. Acta  104, 298 (1965).
  79. Preferential immune response to D-amino acid residues in poly-DL- amino acid determinants. I. Schechter and M. Sela, Biochim. Biophys. Acta  104, 301 (1965).
  80. Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. H.O. McDevitt and M. Sela, J. Exp. Med. 122, 517 (1965).
  81. Use of urea in the purification of antibodies. L.I. Slobin and M. Sela, Biochim. Biophys. Acta  107, 593 (1965).
  82. Immunogenicity and the role of size: response of guinea pigs to oligo-tyrosine and tyrosine derivatives. F. Borek, Y. Stupp and M. Sela, Science 150, 1177 (1965).
  83. On the role of charge in antigen-antibody precipitin reactions. E. Hurwitz, S. Fuchs and M. Sela, Biochim. Biophys. Acta  111, 512 (1965).
  84. Synthesis and antigenic properties of sugar-polypeptide conjugates. E. Rude, O. Westphal, E. Hurwitz, S. Fuchs and M. Sela, Immunochemistry 3, 137 (1966).
  85. New synthesis of poly-L-glutamic acid and poly-L-glutamyl proteins. M. Wilchek, A. Frensdorff and M. Sela, Arch. Biochem. Biophys. 113, 742 (1966).
  86. Isolation and characterization of a neurotoxin from Vipera Palestinae venom. C. Moroz, A. de Vries and M. Sela, Biochim. Biophys. Acta  124, 136 (1966).
  87. Dependence of the chemical nature of antibodies on the net electrical charge of antigens. M. Sela and E. Mozes, Proc. Natl. Acad. Sci. U.S. 55, 445 (1966).
  88. Recovery of antigenic activity upon reoxidation of completely reduced polyalanyl rabbit immunoglobulin G. M.H. Freedman and M. Sela, J. Biol. Chem. 241, 2383 (1966).
  89. Pyridoxal-specific antibodies obtained with a synthetic pyridoxyl-poly-peptide conjugate. H. Ungar-Waron and M. Sela, Biochim. Biophys. Acta  124, 147 (1966).
  90. Isolation and characterization of active fragments obtained by cleavage of immunoglobulin G with cyanogen bromide. H.J. Cahnmann, R. Arnon and M. Sela, J. Biol. Chem. 241, 3247 (1966).
  91. The localization of antigen in relation to specific antibody- producing cells. I. Use of a synthetic polypeptide ((T,G)-A--L) labelled with iodine-125. H.O. McDevitt, A.B. Askonas, J.H. Humphrey, I. Schechter and M. Sela, Immunology 11, 337 (1966).
  92. Soluble antigen-antibody complexes as intermediates in the purification of antibodies using 8 M urea. M.H. Freedman, L.I. Slobin, J.B. Robbins and M. Sela, Arch. Biochem. Biophys. 116, 82 (1966).
  93. Combining sites of antibodies with L-alanine and D-alanine peptide specificity and the effect of serum proteolytic activity on their estimation. I. Schechter, B. Schechter and M. Sela, Biochim. Biophys. Acta  127, 438 (1966).
  94. The immune response of inbred strains of guinea pigs to polylysyl rabbit serum albumin. S. Ben-Efraim, R. Arnon and M. Sela, Immunochemistry 3, 491 (1966).
  95. Chemical modification of human erythrocytes by attachment of tyrosine and alanine peptides. A. Rimon and M. Sela, Biochim. Biophys. Acta  124, 408 (1966).
  96. Studies on the types of immune response to synthetic antigens in guinea pigs. Y. Stupp, F. Borek and M. Sela, Immunology 11, 561 (1966).
  97. Inactivation of poly-DL-alanyl bacteriophage T4 with antisera specific towards poly-DL-alanine. J. Haimovich and M. Sela J. Immunology 97, 338 (1966).
  98. Recovery of specific activity upon reoxidation of completely reduced polyalanyl rabbit antibody. M.H. Freedman and M. Sela, J. Biol. Chem. 241, 5225 (1966).
  99. Distribution of antibody activities after simultaneous immunization with two antigens. E. Mozes and M. Sela, Biochim. Biophys. Acta  130, 254 (1966).
  100. Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. J.B. Robbins, J. Haimovich and M. Sela, Immunochemistry 4, 11 (1967).
  101. Modification of the carboxyl groups of ribonuclease by attachment of glycine or alanylglycine. M. Wilchek, A. Frensdorff and M. Sela, Biochemistry 6, 247 (1967).
  102. Correlation between net charge of antigens and electrophoretic mobility of immunoglobulin M antibodies. J.B. Robbins, E. Mozes, A. Rimon and M. Sela, Nature 213, 1013 (1967).
  103. Differences in immune response to synthetic antigens in two inbred strains of guinea pigs. S. Ben-Efraim, S. Fuchs and M. Sela, Immunology 12, 573 (1967).
  104. Preferential formation of antibodies specific toward D-amino acid residues upon immunization with poly-DL-peptidyl proteins. I. Schechter and M. Sela, Biochemistry 6, 897 (1967).
  105. Antibodies elicited with conjugates of nucleosides with synthetic polypeptides. H. Ungar-Waron, E. Hurwitz, J.-C. Jaton and M. Sela, Biochim. Biophys. Acta  138, 513 (1967).
  106. Formation and isolation of rabbit antibodies to a synthetic antigen of low molecular weight. F. Borek, Y. Stupp and M. Sela, J. Immunology 98, 739 (1967).
  107. Synthetic antigens composed exclusively of L- or D-amino acids. I. Effect of optical configuration on the immunogenicity of synthetic polypeptides in mice. C.A. Janeway, Jr., and M. Sela, Immunology 13, 29 (1967).
  108. The localization of antigen in lymph nodes and its relation to specific antibody-producing cells. II. Comparison of iodine-125 and tritium labels. J.H. Humphrey, B.A. Askonas, Y. Auzins, I. Schechter and M. Sela, Immunology 13, 71 (1967).
  109. Specificity of immunological tolerance to poly-DL-alanyl proteins. S. Bauminger, I. Schechter and M. Sela, Immunochemistry 4, 169 (1967).
  110. Equine anti-hapten antibody. IV. The effects of polyalanylation on affinity. F. Karush and M. Sela, Immunochemistry 4, 259 (1967).
  111. Biological activity on the cleavage product of human immunoglobulin G with cyanogen bromide. M. Lahav, R. Arnon and M. Sela, J. Exp. Med. 125, 787 (1967).
  112. Synthesis, characterization and enzymatic properties of poly-L-lysyl ribonuclease. A. Frensdorff and M. Sela, Eur. J. Biochem. 1, 267 (1967).
  113. A comparative study of basic, acidic and neutral polypeptidyl RNases, including polyarginyl and polyhistidyl derivatives. A. Frensdorff, M. Wilchek and M. Sela, Eur. J. Biochem. 1, 281 (1967).
  114. Anti-penicilloyl antibodies: Detection with penicilloylated bacteriophage and isolation with a specific immunoadsorbent. J. Haimovich, M. Sela, J.M. Dewdney and F.R. Batchelor, Nature 214, 1369 (1967).
  115. Heterogeneity of the light chains of rabbit immunoglobulin G fractions and of a series of antibodies directed towards antigens of differing complexity. E. Mozes, J.B. Robbins and M. Sela, Immunochemistry 4, 239 (1967).
  116. Further studies on the immunogenicity of D-amino acid polymers. Y. Stupp and M. Sela, Biochim. Biophys. Acta  140, 349 (1967).
  117. Immunogenicity of hapten conjugates of poly-D-tyrosine. F. Borek,Y. Stupp and M. Sela, Biochim. Biophys. Acta  140, 360 (1967).
  118. Cytolipin H-specific antibodies obtained with a synthetic polypeptide conjugate. R. Arnon, M. Sela, E.S. Rachaman and D. Shapiro, Eur. J. Biochem. 2, 79 (1967).
  119. Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. H.O. McDevitt and M. Sela, J. Exp. Med. 126, 969 (1967).
  120. Immune response to multichain poly-DL-alanine. A. Rimon, D. Teitelbaum, S. Bauminger and M. Sela, Immunochemistry 4, 505 (1967).
  121. Comparison of IgG and IgM antibodies specific for uridine. J.-C. Jaton, H. Ungar-Waron and M. Sela, Eur. J. Biochem. 2, 106 (1967).
  122. Action of papain on normal rabbit immunoglobulin M. H. Ungar-Waron, J.-C. Jaton and M. Sela, Biochim. Biophys. Acta  140, 542 (1967).
  123. On the non-essentiality of two specific disulfide bonds in ribonuclease for its biological activity. H. Neumann, I.Z. Steinberg, J.R. Brown, R.F. Goldberger and M. Sela, Eur. J. Biochem. 3, 171 (1967)
  124. Preparation and enzymatic characterization of poly-DL-alanyl myosin. I.S. Edelman, E. Hoffer, S. Bauminger and M. Sela, Arch. Biochem. Biophys. 123, 211 (1968).
  125. Preparation et proprietes de derives poly-DL-alanyles d'un inhibiteur de la trypsine (inhibiteur de Kunitz et Northrop). R. Acher, J. Chauvet, R. Arnon and M. Sela, Eur. J. Biochem. 3, 476 (1968).
  126. Studies on the competence of single cells to produce antibodies of two specificites. H. Gershon, S. Bauminger, M. Sela and M. Feldman, J. Exp. Med. 128, 223 (1968).
  127. Role of the net electrical charge of the complete antigen in determining the chemical nature of anti-p-azobenzenearsonate antibodies. E. Rude, E. Mozes and M. Sela, Biochemistry 7, 2971 (1968).
  128. Cleavage of horse immunoglobulin by cyanogen bromide. M.L. Ernst, R. Arnon and M. Sela, Immunochemistry 5, 513 (1968).
  129. Recovery of antibody activity upon reoxidation of completely reduced polyalanyl heavy chain and its Fd fragment derived from anti-2,4-dinitrophenyl antibody. J.-C. Jaton, N.R. Klinman, D. Givol and M. Sela, Biochemistry 7, 4185 (1968).
  130. Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline. J.-C. Jaton and M. Sela, J. Biol. Chem. 243, 5616 (1968).
  131. Disc electrophoresis patterns of the Fd fragment of rabbit immunoglobulin fractions and of purified antigens. S. Segal, D. Givol and M. Sela, Immunochemistry 6, 229 (1969).
  132. Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate. R. Arnon and M. Sela, Proc. Natl. Acad. Sci. U.S. 62, 163 (1969).
  133. Combining sites of IgG and IgM antibodies of poly-D-alanyl specificity. J. Haimovich, I. Schechter and M. Sela, Eur. J. Biochem. 7, 537 (1969).
  134. Specificity of immunological tolerance to synthetic polypeptides. S. Bauminger and M. Sela, Israel J. Med. Sci. 5, 177 (1969).
  135. Resolution of mouse and human immunoglobulin G into two fractions by chromatography on diethylaminoethyl-Sephadex. Relation of mouse antibody type to the antigen charge. E. Mozes and M. Sela, Israel J. Med. Sci. 5, 267 (1969).
  136. Protein-bacteriophage conjugates: Application in detection of antibodies and antigens. J. Haimovich and M. Sela, Science 164, 1279 (1969).
  137. Inactivation of bacteriophage T4, of poly-D-alanyl bacteriophage and of penicilloyl bacteriophage by immunospecifically isolated IgM and IgG antibodies. J. Haimovich and M. Sela, J. Immunology 103, 45 (1969).
  138. Immunological properties of a collagen-like synthetic polypeptide. F. Borek, J. Kurtz and M. Sela, Biochim. Biophys. Acta  188, 314 (1969).
  139. The nature of the antigenic determinant in genetic control of the antibody response. E. Mozes, H.O. McDevitt, J.-C. Jaton and M. Sela, J. Exp. Med. 130, 493 (1969).
  140. The genetic control of antibody specificity. E. Mozes, H.O. McDevitt, J.-C. Jaton and M. Sela, J. Exp. Med. 130, 1263 (1969).
  141. Antibody combining sites to a series of peptide determinants increasing size and defined structure. B. Schechter, I. Schechter and M. Sela, J. Biol. Chem. 245, 1438 (1970).
  142. In vitro induction of a primary response to the dinitrophenyl determinant. S. Segal, A. Globerson, M. Feldman, J. Haimovich and M. Sela, J. Exp. Med. 131, 93 (1970).
  143. Induction of tolerance to poly-DL-alanyl ribonuclease in adult rats. D.W. Scott, B.H. Waksman, S. Bauminger and M. Sela, Immunochemistry 7, 357 (1970).
  144. Hemagglutination-inhibition studies of the combining sites of anti-peptide antibodies in mice and rats. E. Clerici, I. Schechter and M. Sela, Immunology 19, 267 (1970).
  145. Preparation of protein-bacteriophage conjugates and their use in detection of anti-protein antibodies. J. Haimovich, E. Hurwitz, N. Novik and M. Sela, Biochim. Biophys. Acta  207, 115 (1970).
  146. Use of protein-bacteriophage conjugates for detection and quantitation of proteins. J. Haimovich, E. Hurwitz, N. Novik and M. Sela, Biochim. Biophys. Acta  207, 125 (1970).
  147. Studies on synthetic polypeptide antigens derived from multichain polyproline. I. Immunogenic and tolerogenic capacity of antigens composed wholly or partly of D-amino acids. J. Medlin, J.H. Humphrey and M. Sela, Folia Biologica 16, 145 (1970).
  148. Studies on synthetic polypeptide antigens derived from multichain polyproline. II. Metabolism and localization. J. Medlin, J.H. Humphrey and M. Sela, Folia Biologica 16, 156 (1970).
  149. Specific fractionation of antibodies to peptide determinants. B. Schechter, I. Schechter and M. Sela, Immunochemistry 7, 587 (1970).
  150. Antibodies of different specificities in normal rabbit sera. J. Haimovich, R. Tarrab, A. Sulica and M. Sela, J. Immunology 104, 1033 (1970).
  151. Detection of anti-p-azobenzenearsonate antibodies with chemically modified bacteriophage. M.J. Becker, A.Conway-Jacobs, M. Wilchek, J. Haimovich and M. Sela, Immunochemistry 7, 741 (1970).
  152. Reduction in immunological manifestations of 6-aminopenicillanic acid by treatment with water-insoluble pronase. S. Shaltiel, R. Mizrahi, Y. Stupp and M. Sela, Eur. J. Biochem. 14, 509 (1970).
  153. Basic encephalitogenic protein: A simplified purification on sulfoethyl-Sephadex. T. Hirshfeld, T. Teitelbaum, R. Arnon and M. Sela, FEBS Letters 7, 317 (1970).
  154. Cellular basis of the genetic control of immune responses to synthetic polypeptides. I. Differences in frequency of splenic precursor cells specific for a synthetic polypeptide derived from multichain polyproline, ((T,G)-Pro--L), in high and low responder inbred mouse strains. E. Mozes, G.M. Shearer and M. Sela, J. Exp. Med. 132, 613 (1970).
  155. Search for antibodies against the carbohydrate portion of two mouse myeloma proteins. F. Melchers and M. Sela, Immunochemistry 7, 749 (1970).
  156. Immunological comparison of bird and human lysozymes and of their "loop" regions. E. Maron, R. Arnon, M. Sela, J.-P. Perin and P. Jolles, Biochim. Biophys. Acta  214, 222 (1970).
  157. A sensitive technique for detecting and quantitating the peptide hormone angiotensin II and its antibodies by using chemically modified bacteriophage and activated Sepharose. E. Hurwitz, F.M. Dietrich and M. Sela, Eur. J. Biochem. 17, 273 (1970).
  158. Cellular aspects of the inverse relationship between the net charge of immunogens and of antibodies elicited. M. Sela, E. Mozes, G.M. Shearer and Y. Karniely, Proc. Natl. Acad. Sci. U.S. 67, 1288 (1970).
  159. Extrinsic cotton effect and immunological properties of the p-azobenzenearsonate hapten attached to a helical amino acid copolymer. A. Conway-Jacobs, B. Schechter and M. Sela, Biochemistry 9, 4870 (1970).
  160. Antibodies to transfer RNA obtained with covalently linked tRNA conjugates. B. Bonavida, S. Fuchs and M. Sela, Biochem. Biophys. Res. Comm. 41, 1335 (1970).
  161. Chemical and immunological characterization of a unique antigenic region in lysozyme. E. Maron, C. Shiozawa, R. Arnon and M. Sela, Biochemistry 10, 763 (1971).
  162. Detection of antibody-like structures on cell surfaces with chemically modified bacteriophages. A. Sulica, J. Haimovich and M. Sela, J. Immunology 106, 721 (1971).
  163. Strain dependent differences in the specificity of antibody responses towards lysozyme. E. Mozes, E. Maron, R. Arnon and M. Sela, J. Immunology 106, 862 (1971).
  164. Stimulation in vitro with protein carrier of antibodies against a hapten. A. Sulica, R. Tarrab and M. Sela, Science 171, 1165 (1971).
  165. Cellular basis of the genetic control of immune responses to synthetic polypeptides. II. Frequency of immunocompetent precursors specific for two distinct regions within (Phe,G)-Pro--L, a synthetic polypeptide derived from multichain polyproline in inbred mouse strains. G.M. Shearer, E. Mozes and M. Sela, J. Exp. Med. 133, 216 (1971).
  166. Dose response and induction of tolerance to the synthetic antigen (T,G)-A--L in adult rabbits. M. Sela, S. Fuchs, R. Maron and B. Gertner, Eur. J. Immunol. 1, 36 (1971).
  167. The synthesis and circular dichroism of a series of peptides possessing the structure (L-tyrosyl-L-alanyl-L-glutamyl)n. B. Schechter, I. Schechter, J. Ramachandran, A.Conway-Jacobs and M. Sela, Eur. J. Biochem. 20, 301 (1971).
  168. Synthetic antigens with sequential and conformation-dependent determinants containing the same L-tyrosyl-L-alanyl-L-glutamyl sequence. B. Schechter, I. Schechter, J. Ramachandran, A. Conway-Jacobs, M. Sela, E. Benjamini and M. Shimizu, Eur. J. Biochem. 20, 309 (1971).
  169. Conformational changes in a synthetic antigen induced by specific antibodies. B. Schechter, A. Conway-Jacobs and M. Sela, Eur. J. Biochem. 20, 321 (1971).
  170. A comparison of the antigenic specificity of random and ordered linear polypeptides composed of L-tyrosine, L-alanine and L-glutamic acid. A. Conway-Jacobs, B. Schechter and M. Sela, Eur. J. Biochem. 20, 325 (1971).
  171. Specific excitation energy transfer from antibodies to dansyl- labeled antigen. Studies with the "loop" peptide of hen egg-white lysozyme. I. Pecht, E. Maron, R. Arnon and M. Sela, Eur. J. Biochem. 19, 368 (1971).
  172. Anti-inosine antibodies. H. Inouye, S. Fuchs, M. Sela and U.Z. Littauer, Biochim. Biophys. Acta  240, 594 (1971).
  173. Inosine-coated bacteriophage T4. B. Bonavida, S. Fuchs, H. Inouye and M. Sela, Biochim. Biophys. Acta  240, 604 (1971).
  174. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. D. Teitelbaum, A.Meshorer, T. Hirshfeld. R. Arnon and M. Sela, Eur. J. Immunol. 1, 242 (1971).
  175. Cell proliferation and antibody production in the secondary response in vitro towards a defined hapten. R. Tarrab, A. Sulica, J. Haimovich and M. Sela, Eur. J. Immunol. 1, 231 (1971).
  176. Effect of phytohemagglutinin on thymidine incorporation and antibody production in the secondary response in vitro towards a defined hapten. A. Sulica, R. Tarrab, J. Haimovich and M. Sela, Eur. J. Immunol. 1, 236 (1971).
  177. Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. R. Arnon, E. Maron, M. Sela and C.B. Anfinsen, Proc. Natl. Acad. Sci. U.S. 68, 1450 (1971).
  178. Antibody response to polyalanyl determinants in tolerant rabbits. R. Tarrab, I. Schechter and M. Sela, Immunochemistry 8, 1107 (1971).
  179. Solubilization of lymphocyte and thymocyte antigens by a reversible chemical modification. Z. Eshhar, M. Gafni, D. Givol and M. Sela, Eur. J. Immunol. 1, 323 (1971).
  180. On the immunological properties of penicillins. S. Shaltiel, R. Mizrahi and M. Sela, Proc. Roy. Soc. B 179, 411 (1971)
  181. Antibodies against polyalanyl determinants attached to negatively or positively charged carriers. A. Licht, B. Schechter and M. Sela, Eur. J. Immunol. 1, 351 (1971).
  182. Stimulation in vivo and in vitro of anti-dinitrophenyl antibodies with homologous protein carriers devoid of hapten. P.H. Strausbauch, R. Tarrab, A. Sulica and M. Sela, J. Immunology 108, 236 (1972).
  183. Nucleoside-coated bacteriophage T4: A method for the detection and characterization of anti-nucleoside antibodies. B. Bonavida, S. Fuchs and M. Sela, J. Imm. Meth. 1, 155 (1972).
  184. Use of immunologically modified bacteriophage T4 in detection of antibodies to nucleic acids. D. Gurari, B. Bonavida, M.J. Taussig, S. Fuchs and M. Sela, Eur. J. Biochem. 26, 247 (1972).
  185. Lipolytic activity of bovine growth hormone bound to Sepharose beads. J.P. Hecht, J.M. Dellacha, J.A. Santome, A.C. Paladini, E. Hurwitz and M. Sela, FEBS Letters 20, 83 (1972).
  186. Contribution of different cell types to the genetic control of immune responses as a function of the chemical nature of the polymeric side chains (poly-L-prolyl and poly-DL-alanyl) of synthetic immunogens. G.M. Shearer, E. Mozes and M. Sela, J. Exp. Med. 135, 1009 (1972).
  187. Stimulation of anti-hapten response by heterologous protein devoid of hapten. M. Bustin, R. Tarrab, P.H. Strausbauch, A. Sulica and M. Sela, Eur. J. Immunol. 2, 288 (1972).
  188. Dynamics of hapten-antibody interaction. Studies on a myeloma protein with anti-2,4-dinitrophenyl specificity. I. Pecht, D. Givol and M. Sela, J. Mol. Biol. 68, 241 (1972).
  189. Receptors for histamine can be detected on the surface of selected leukocytes. K.L. Melmon, H.R. Bourne, J. Weinstein and M. Sela, Science 177, 707 (1972).
  190. Studies on the mechanism of antigenic competition: Analysis of competition between synthetic polypeptide antigens. M.J. Taussig, E. Mozes, G.M. Shearer and M. Sela Eur. J. Immunol. 2, 448 (1972).
  191. Multichain polyproline coated with histidyl and glutamyl residues - A potent synthetic immunogen. S. Shaltiel, E. Mozes and M. Sela, Israel J. Chem. 10, 627 (1972).
  192. Thymus independence of slowly metabolized immunogens. M. Sela, E. Mozes and G.M. Shearer, Proc. Natl. Acad. Sci. U.S. 69, 2696 (1972).
  193. Protection against experimental allergic encephalomyelitis by treatment with the basic protein of brain followed by a basic synthetic polypeptide. D. Teitelbaum, C. Webb, A. Meshorer, R. Arnon and M. Sela, Nature 240, 564 (1972).
  194. Regulation of antibody response by cells expressing histamine receptors. G.M. Shearer, K.L. Melmon, Y. Weinstein and M. Sela, J. Exp. Med. 136, 1302 (1972).
  195. Specific antibodies to dinucleotides and trinucleotides. B. Bonavida, S. Fuchs, M. Sela, P.W. Roddy and H.A. Sober, Eur. J. Biochem. 31, 534 (1972).
  196. Cooperation of antigenic determinants in intact mice and interference by antigenic competition. M.J. Taussig, E. Mozes, G.M. Shearer and M. Sela, Eur. J. Immunol. 2, 577 (1972).
  197. Characterization and partial purification of antigenic components solubilized by a reversible chemical modification from rat thymocyte membrane. M. Bustin, Z. Eshhar and M. Sela, Eur. J. Biochem. 31, 541 (1972).
  198. Immunochemical detection of prostaglandins with prostaglandin-coated bacteriophage T4 and by radioimmunoassay. F. Dray, E. Maron, S.A. Tillson and M. Sela, Anal. Biochem. 50, 399 (1972).
  199. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. D. Teitelbaum, C. Webb, A.Meshorer, R. Arnon and M. Sela, Eur. J. Immunol. 3, 273 (1973).
  200. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. C. Webb, D. Teitelbaum, R. Arnon and Eur. J. Immunol. 3, 279 (1973).
  201. Genetic control of immune response in mice to derivatives of multichain polyproline differing in the optical configuration of component amino acids. E. Mozes, M. Sela and H.O. McDevitt, Eur. J. Immunol. 3, 1 (1973).
  202. Genetic control of immune response towards the loop region of lysozyme. E. Maron, H.I. Scher, E. Mozes, R. Arnon and M. Sela, J. Immunology 111, 101 (1973).
  203. Antigenicity of dinitrophenyl polyproline. D. Gurari, H. Ungar-Waron and M. Sela, Eur. J. Immunol. 3, 196 (1973).
  204. Role of a rigid polyproline spacer inserted between hapten and carrier in the induction of anti-hapten antibodies. H. Ungar-Waron, D. Gurari, E. Hurwitz and M. Sela, Eur. J. Immunol. 3, 201 (1973).
  205. Specific leukocyte receptors for small endogenous hormones. Y. Weinstein, K.L. Melmon, H.R. Bourne and M. Sela, J. Clin. Invest. 52, 1349 (1973).
  206. The role of thymocytes and bone marrow cells in defining the response to the dinitrophenyl hapten attached to positively and negatively charged synthetic polypeptide carriers: Cell fractionation over charged columns. Y. Karniely, E. Mozes, G.M. Shearer and M. Sela, J. Exp. Med. 137, 183 (1973).
  207. Correlation between strain differences in susceptibility to experimental allergic encephalomyelitis and the immune response to encephalitogenic protein in inbred guinea pigs. C. Webb, D. Teitelbaum, R. Arnon and M. Sela, Imm. Comm. 2, 185 (1973).
  208. The specificity of cellular immunity: Studies in guinea pigs using defined tetrapeptides containing p-azobenzenearsonate-L-tyrosine. M.J. Becker, H. Levin and M. Sela, Eur. J. Immunol. 3, 131 (1973).
  209. Nuclease coated bacteriophage: A sensitive tool for studying antigenic reactivity of synthetic sequence fragments. S. Fuchs, M. Sela and C.B. Anfinsen, Arch. Biochem. Biophys. 154, 601 (1973).
  210. Antigenic competition and genetic control of the immune response. A hypothesis for intramolecular competition. M.J. Taussig, E. Mozes, G.M. Shearer and M. Sela, Cell Immunol. 8, 299 (1973).
  211. Genetic control of immune responses to synthetic polypeptides in mice: Cellular analysis of the phenotypic correction of the Ir-3 gene defect by polyadenylic-polyuridylic acid. E. Mozes, G.M. Shearer, M. Sela and W. Braun, J. Immunology 111, 439 (1973).
  212. Penicillin antibodies and immunoglobulin production in newborn infants: Studies using chemically modified bacteriophage. S. Levin, Y. Altman, E. Nir, E. Hurwitz and M. Sela, Pediatric Res. 7, 675 (1973).
  213. Sphingomyelin specific antibodies elicited by synthetic conjugates. D. Teitelbaum, R. Arnon, M. Sela, Y. Rabinsohn and D. Shapiro, Immunochemistry 10, 735 (1973).
  214. Preparation of antisera to a-fetoprotein making use of estradiol affinity column. R. Arnon, E. Teicher, M. Bustin and M. Sela, FEBS Letters 32, 335 (1973).
  215. Cellular studies of the genetic control of immune responses towards the loop region of lysozyme. E. Mozes, G.M. Shearer, E. Maron, R. Arnon and M. Sela, J. Immunology 111, 1429 (1973).
  216. Immune response to the collagen-like synthetic ordered polypeptide (LPro-Gly-LPro)n. A. Maoz, S. Fuchs and M. Sela, Biochemistry 9, 4238 (1973).
  217. On immunological cross-reactions between the synthetic ordered polypeptide (LPro-Gly-LPro)n and several collagens. A. Maoz, S. Fuchs and M. Sela, Biochemistry 9, 4246 (1973).
  218. Cytotoxic activity of antibodies to a collagen-like synthetic poly-tripeptide on cells in tissue culture. A. Maoz, H. Dym, S. Fuchs and M. Sela, Eur. J. Immunol. 3, 839 (1973).
  219. Shape and volume of anti-poly-D-alanyl antibodies in the presence and absence of tetra-D-alanine as followed by small angle X-ray scattering. I. Pilz, O. Kratky, A. Licht and M. Sela, Biochemistry 12, 4998 (1973).
  220. Detection of inosine-containing tRNA species by affinity chromatography on columns of anti-inosine antibodies. H. Inouye, S. Fuchs, M. Sela and U.Z. Littauer, J. Biol. Chem. 248, 8125 (1973).
  221. Immunogenicity and antigenic specificity of a glutaraldehyde cross-linked transfer RNA-protein conjugate. A. Aharonov, S. Fuchs, B.D. Stollar and M. Sela, Eur. J. Biochem. 42, 73 (1974).
  222. Immunological unresponsiveness induced in adult mice to synthetic poly-peptides built on multichain polyproline and multichain polyalanine. B. Bonavida, E. Mozes, G.M. Shearer and M. Sela, Immunochemistry 11, 347 (1974).
  223. The role of thymus cells in the immune response to poly(Tyr,Glu)-polyDLAla--polyLys as a function of the genetic constitution of the mouse strain. L. Lichtenberg, E. Mozes, G.M. Shearer and M. Sela, Eur. J. Immunol. 4, 430 (1974).
  224. The role of the thymus in a genetically controlled defect of the immune response at the carrier level. E. Mozes and M. Sela, Proc. Natl. Acad. Sci. U.S. 71, 1574 (1974).
  225. Cellular analysis of the phenotypic correction of the genetically controlled low immune response to the polyproline determinant by macrophages. F.W. Falkenberg, A. Sulica, G.M. Shearer, E. Mozes and M. Sela, Cell Immunol. 12, 271 (1974).
  226. Antigenicity of p-azobenzenearsonate-containing oligopeptides in rabbits. H. Levin, M. Becker and M. Sela, Eur. J. Biochem. 44, 271 (1974).
  227. Thymus independence of a collagen-like synthetic polypeptide and of collagen, and the need for thymus and bone marrow cell cooperation in the immune response to gelatin. S. Fuchs, E. Mozes, A. Maoz and M. Sela, J. Exp. Med. 139, 148 (1974).
  228. Tolerance to thymus-independent antigens. Characteristics of induction of tolerance to thymus-independent synthetic polypeptides. E. Mozes, M. Sela and M.J. Taussig, Immunology 27, 641 (1974).
  229. Antibodies to yeast phenylalanine transfer ribonucleic acid are specific for the odd nucleoside Y in the anticodon loop. S. Fuchs, A. Aharonov, M. Sela, F. von der Haar and F. Cramer, Proc. Natl. Acad. Sci. U.S. 71, 2800 (1974).
  230. The genetic control of the immune response to different antigenic determinants within the synthetic polypeptide poly(His,Glu)-polyPro--polyLys. E. Mozes, S. Shaltiel and M. Sela, Eur. J. Immunol. 4, 463 (1974).
  231. Antibody response of inbred mouse strains to ordered tetrapeptides of tyrosine and glutamic acid attached to multichain polyalanine or poly-proline: Tyr-Tyr-Glu-Glu is a major determinant of the random poly(Tyr,Glu)-polyDLAla--polyLys. E. Mozes, M. Schwartz and M. Sela, J. Exp. Med. 140, 349 (1974).
  232. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. D. Teitelbaum, C. Webb, M. Bree, A. Meshorer, R. Arnon and M. Sela, Clin. Imm. Immunopathol. 3, 256 (1974).
  233. Lymphocytes sensitized to basic encephalitogen in multiple sclerosis patients unresponsive to steroid therapy. C. Webb, D. Teitelbaum, O. Abramsky, R. Arnon and M. Sela, Lancet 1974, II, 66.
  234. Genetic control of the immune response to a thymus independent synthetic polypeptide. A.-M. Schmitt-Verhulst, E. Mozes and M. Sela, Immunogenetics 1, 357 (1974).
  235. Specific cytotoxicity of drugs chemically linked to antibody. R. Levy, E. Hurwitz, R. Maron, R. Arnon and M. Sela, Transpl. Proc. 23, 189 (1975), Transplantation Today, Vol. III, ed. by M. Schlesinger and R.E. Billingham, Grune and Stratton, New York, p. 485, 1975.
  236. Shape and volume of fragments Fab' and (Fab')2 of anti-poly(D-alanyl) antibodies in the presence and absence of tetra-D-alanine as determined by small-angle x-ray scattering. I. Pilz, O. Kratky, A. Licht and M. Sela, Biochemistry 14, 1326 (1975).
  237. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities. E. Hurwitz, R. Levy, R. Maron, M. Wilchek, R. Arnon and M. Sela, Cancer Research 35, 1175 (1975).
  238. The specific cytotoxic effects of daunomycin conjugated to anti-tumor antibodies. R. Levy, E. Hurwitz, R. Maron, R. Arnon and M. Sela, Cancer Research 35, 1182 (1975).
  239. Binding of histamine- and other ligand-conjugated macromolecules to lymphocytes. G.E. Matthyssens, E. Hurwitz, D. Givol and M. Sela, Molecular and Cellular Biochemistry 7, 119 (1975).
  240. Genetic control of immune response. The dose of antigen given in aqueous solution is critical in determining which mouse strain is high responder to poly(LTyr,LGlu)-poly(LPro)--poly(LLys). S. Jormalainen, E. Mozes and M. Sela, J. Exp. Med. 141, 1057 (1975).
  241. Analysis of the role of different cell types in the genetic regulation of antibody production to the thymus independent synthetic polypeptide poly(DTyr,DGlu)-poly(DPro)--poly(DLys). A.-M. Schmitt-Verhulst, E. Mozes and M. Sela, Eur. J. Immunol. 5, 496 (1975).
  242. Inverse relationship between net electric charge on the antigen and that on the sensitized cell in cellular immune response - demonstration with basic encephalitogen of the brain. D. Teitelbaum, C. Webb, H. Rauch, Y. Karniely, R. Arnon and M. Sela, J. Exp. Med. 142, 701 (1975).
  243. Genetic control of the murine cell-mediated immune response in vivo. II. H-2 linked responsiveness to the synthetic polypeptide poly(Tyr,Glu)- poly(DL-Ala)--poly(Lys). S. Davis, G.M. Shearer, E. Mozes and M. Sela, J. Immunology 115, 1530 (1975).
  244. Lack of inverse relationship between the net charge of T-independent immunogens and the responding spleen cells. F.W. Falkenberg, Y. Karniely, A.-M. Schmitt-Verhulst, E. Mozes and M. Sela, J. Immunology 115, 1538 (1975).
  245. Genetically controlled immune responses of inbred mouse strains to conjugates of the ordered peptides (Tyr-Tyr-Glu-Glu) and (Tyr-Glu-Tyr-Glu) with multichain poly-DL-alanine as compared with the response to the random (T,G)-A--L. M. Schwartz, E. Mozes and M. Sela, Eur. J. Immunol. 5, 866 (1975).
  246. Fab dimers of anti-tumor immunoglobulins as covalent carriers of daunomycin. E. Hurwitz, R. Maron, R. Arnon and M. Sela, Cancer BioChemistry BioPhysics 1, 197 (1976).
  247. Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. C. Webb, D. Teitelbaum, A. Herz, R. Arnon and M. Sela, Immunochemistry 13, 333 (1976).
  248. Immunological cross-reactivity of antibodies to a synthetic undecapeptide of carcinoembryonic antigen with the intact protein and with human sera. R. Arnon, M. Bustin, E. Calef, S. Chaitchik, J. Haimovich, N. Novik and M. Sela, Proc. Natl. Acad. Sci. U.S. 73, 2123 (1976).
  249. Reconstitution of genetically regulated responses against random and ordered synthetic polypeptides by methylated bovine serum albumin as analysed by isoelectric focusing. M. Cramer, M. Schwartz, E. Mozes and M. Sela, Eur. J. Immunol. 6, 618 (1976).
  250. Varied effects of polyadenylic-polyuridylic acid on immune responses. M. Sela and E. Mozes, Biochimie 58, 173 (1976).
  251. Determinants of antigenic molecules responsible for the genetically controlled regulation of immune responses. M. Schwartz, C. Waltenbaugh, M. Dorf, R. Cesla, M. Sela and B. Benacerraf, Proc. Natl. Acad. Sci. U.S. 73, 2862 (1976).
  252. Genetic control of immune responsiveness to poly-(L-Pro)--poly(L-Lys) derived polypeptides by histocompatibility-linked immune response genes in the rat. E. Gunther, E. Mozes, E. Rude and M. Sela, J. Immunology 117, 2047 (1976).
  253. In vitro proliferative reactions by lymphocytes from both responder and "low" responder mice to (T,G)-A--L. J.J. Oppenheim, E. Mozes and M. Sela, in M. Feldman and A. Globerson, eds. "Immune Reactivity of Lymphocytes", Plenum Press, 1976, p. 261.
  254. Role of antigenic structure in cell to cell cooperation. M. Schwartz, R.J. Hooghe, E. Mozes and M. Sela, Proc. Natl. Acad. Sci. U.S. 73, 4184 (1976).
  255. IgG and IgM. Antibodies in normal and leukemic cattle. Z. Trainin, H. Ungar-Waron, R. Meirom, A. Barnea and M. Sela, J. Comp. Pathol. 86, 571 (1976).
  256. Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. H. Langbeheim, R. Arnon and M. Sela, Proc. Natl. Acad. Sci. U.S. 73, 4636 (1976).
  257. A simple fluorescent method to determine complement-mediated liposome immune lysis. M. Smolarsky, D. Teitelbaum, M. Sela and C. Gitler, J. Immunol. Methods 15, 255 (1977).
  258. Unprimed spleen cell populations recognize macrophage bound antigen with opposite net electric charge. D. Teitelbaum, L. Steinman and M. Sela, Proc. Natl. Acad. Sci. U.S. 74, 1693 (1977).
  259. Strain differences in susceptibility to experimental allergic encephalomyelitis in the immune response to the encephalitogenic determinant in inbred guinea pigs. D. Teitelbaum, C. Webb, R. Arnon and M. Sela, Cellular Immunology 29, 265 (1977).
  260. Daunomycin-immunoglobulin conjugates. Uptake and activity in vitro. E. Hurwitz, R. Maron, R. Arnon, M. Wilchek and M. Sela, Eur. J. Cancer 14, 1213 (1978).
  261. Higher anti-tumor efficacy of daunomycin when linked to dextran. In vitro and in vivo studies. A. Bernstein, E. Hurwitz, R. Maron, R. Arnon, M. Sela and M. Wilchek, J. Natl. Cancer Inst. 60, 379 (1978).
  262. The effect in vivo of chemotherapeutic drug-antibody conjugates in two murine experimental tumor systems. E. Hurwitz, R. Maron, A. Bernstein, M. Wilchek, M. Sela and R. Arnon, Intl. J. Cancer 21, 747 (1978).
  263. Adjuvant effect of a peptidoglycan attached covalently to a synthetic antigen provoking anti-phage antibodies. H. Langbeheim, R. Arnon and M. Sela, Immunology 35, 573 (1978).
  264. Affinity and avidity of antibodies to the random polymer (T,G)-A--L and a related ordered synthetic polypeptide. M. Schwartz, D. Lancet, E. Mozes and M. Sela, Immunochemistry 15, 477 (1978).
  265. The effect of a water-soluble adjuvant on the immune responses to synthetic polypeptides. R. Maron, E. Mozes, S. Fuchs, M. Sela and L. Chedid, Ann. Immunol. 129C, 489 (1978).
  266. The relationship between HLA antigens and Bermuda grass hayfever. C. Geller-Bernstein, R. Kenett, R. Zamir, S. Karlin and M. Sela, Immunogenetics 7, 259 (1978).
  267. The mode of interaction with macrophages of two ordered synthetic polypeptides which differ in their thymus dependency. M. Schwartz, B. Geiger, R. Hooghe, M. Bar-Eli, R. Galily, E. Mozes and M. Sela, Immunology 35, 849 (1979).
  268. Conformational changes induced in anti-poly(L-prolyl) antibodies by oligoproline haptens of different sizes. H.K. Forster and M. Sela, Molecular Immunology 16, 651 (1979).
  269. Binding of anti-tumor immunoglobulins and their daunomycin conjugates to the tumor and its metastases. In vitro and in vivo studies with Lewis lung carcinoma. E. Hurwitz, B. Schechter, R. Arnon and M. Sela, Intl. J. Cancer 24, 461 (1979).
  270. Change in the specificity of antibodies to a random synthetic branched polypeptide in mice tolerant to its ordered analogs. M. Schwartz, B. Parhami, E. Mozes and M. Sela, Proc. Natl. Acad. Sci. U.S. 76, 5286 (1979).
  271. Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly (DL-alanyl)--poly(L-lysine) carrier. L. Chedid, M. Parant, F. Parant, F. Audibert, P. Lefrancier, J. Choay and M. Sela, Proc. Natl. Acad. Sci. U.S. 76, 6557 (1979).
  272. Effect of cleaving interchain disulfide bridges on the radius of gyration and maximum length of anti-poly (D-alanyl) antibodies before and after reaction with tetraalanine hapten. I. Pilz, E. Schwarz, W. Durchschein, A. Licht and M. Sela, Proc. Natl. Acad. Sci. U.S. 77, 117 (1980).
  273. Efficient genetically controlled antibody formation to a synthetic antigen (T,G)-A--L covalently bound to a synthetic adjuvant (MDP). E. Mozes, M. Sela and L. Chedid, Proc. Natl. Acad. Sci. U.S. 77, 4933 (1980).
  274. Anti-viral response elicited by a completely synthetic antigen with built-in adjuvanticity. R. Arnon, M. Sela, M. Parant and L. Chedid, Proc. Natl. Acad. Sci. U.S. 77, 6769 (1980).
  275. Cellular analysis of the specificity of antibodies and of delayed type hypersensitivity responses towards some structurally related synthetic antigens: Boosting is determined by the specificity of T cells. B. Parhami-Seren, G. Strassmann, E. Mozes and M. Sela, Proc. Natl. Acad. Sci. U.S. 79, 5636 (1982).
  276. Report of a preliminary trial of the effectiveness of a synthetic polypeptide (copolymer 1) for the treatment of multiple sclerosis. M.B. Bornstein, A.I. Miller, D. Teitelbaum, R. Arnon and M. Sela, Annals of Neurology 11, 317 (1982).
  277. Effect of a conjugate of daunomycin with antibodies to rat a-fetoprotein on the growth of a-fetoprotein-producing tumor cells. Y. Tsukada, W.K.-D. Bischof, N. Hibi, H. Hirai, E. Hurwitz and M. Sela, Proc. Natl. Acad. Sci. U.S. 79, 621 (1982).
  278. Successful immunization with a totally synthetic diphtheria vaccine. F. Audibert, M. Jolivet, L. Chedid, R. Arnon and M. Sela, Proc. Natl. Acad. Sci. U.S. 79, 5042 (1982).
  279. Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat |-fetoprotein antibodies. Y. Tsukada, E. Hurwitz, R. Kashi, M. Sela, N. Hibi, A. Hara and H. Hirai, Proc. Natl. Acad. Sci. U.S. 79, 7896 (1982).
  280. Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: Characterization of the specificity. G.M. Bahr, Z. Eshhar, R. Ben-Yitzhak, F.Z. Modabber, R. Arnon, M. Sela and L. Chedid, Molecular Immunology 20, 745 (1983).
  281. Fine specificity of antibodies to the synthetic polypeptide (T,G)-A--L and its ordered analogs as followed by solid phase radioimmunoassay. B. Parhami-Seren, E. Mozes and M. Sela, Arch. Biochem. Biophys. 225, 446 (1983).
  282. Antibodies against synthetic peptides of the B subunit of cholera toxin: Cross reaction and neutralization of the toxin. C.O. Jacob, M. Sela and R. Arnon, Proc. Natl. Acad. Sci. U.S. 80, 7611 (1983).
  283. HLA antigens A, B, C and DR in hayfever families of similar environmental conditions. C. Geller-Bernstein, N. Keret, R. Zamir, L. Weissglas, M. Lahav, N. Morton and M. Sela, Experimental and Clinical Immunogenetics 1, 66 (1984).
  284. Survey of immunoglobulin levels in atopic families. C. Geller-Bernstein, R. Kenett, N. Keret, A. Bejerano,B. Reichman, S. Tsur, M. Lahav and M. Sela, Asian Pacific J. Allerg. Immun. 2, 181 (1984).
  285. Survey of immunoglobulin E levels in atopic families in Israel. C. Geller-Bernstein, L. Weisglass, N. Keret, R. Dun, R. Kenett, A. Bejerano, M. Lahav and M. Sela, Israel J. Med. Sci. 20, 1133 (1984).
  286. Both cholera toxin-induced adenylate cyclase activation and cholera toxin biological activity are inhibited by antibodies against related synthetic peptides. C.O. Jacob, M. Sela, M. Pines, S. Hurwitz and R. Arnon, Proc. Natl. Acad. Sci. U.S. 81, 7893 (1984).
  287. The covalent linking of two nucleotide analogues to antibodies. E. Hurwitz, R. Kashi, R. Arnon, M. Wilchek and M. Sela, J. Medicinal Chem. 28, 137 (1985).
  288. Effect of carrier on the immunogenic capacity of synthetic cholera vaccine. C.O. Jacob, R. Arnon and M. Sela, Mol. Immunol. 22, 1333 (1985).
  289. Priming immune response to cholera toxin induced by synthetic peptides. C.O. Jacob, S. Grossfeld, M. Sela and R. Arnon, Eur. J. Immunol. 16, 1057 (1986).
  290. Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins. C.O. Jacob, I. Harari, R. Arnon and M. Sela, Vaccine 4, 95 (1986).
  291. Anti-cholera response elicited by a completely synthetic antigen with built-in-adjuvanticity administered in aqueous solution. C.O. Jacob, R. Arnon and M. Sela, Immunology Letters 14, 43 (1986).
  292. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. M.B. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, S. Wassertheil-Smoller, V. Spada, W. Weiss, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela, The New England Journal of Medicine 317, 408 (1987).
  293. Chemo-immunotherapy of human hepatoma by a conjugate between adriamycin and monoclonal anti-HBs. D. Shouval, R. Adler, J.R. Wands, M. Eliakim, M. Sela and E. Hurwitz, In "Viral Hepatitis and Liver Disease", ed. Zuckerman, A.J., Proceedings 1987 International Symposium on Viral Hepatitis, London, p. 791 (1988), Alan R. Liss, Inc.
  294. "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas' disease. G.B. Henderson, P. Ulrich, A.H. Fairlamb, I. Rosenberg, M. Pereira, M. Sela and A. Cerami, Proc. Natl. Acad. Sci. U.S. 85, 5374 (1988).
  295. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. E. Aboud-Pirak, E. Hurwitz, M.E. Pirak, F. Bellot, J. Schlessinger and M. Sela, Journal Nat. Cancer Inst. 80, 1605 (1988).
  296. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. D. Shouval, R. Adler, J.R. Wands, W. Hurwitz, K.J. Isselbacher and M. Sela, Proc. Natl. Acad. Sci. U.S. 85, 8276 (1988).
  297. Specific inhibition of the T cell response to myelin basic protein by the synthetic copolymer Cop 1. D. Teitelbaum, R. Aharoni, R. Arnon and M. Sela, Proc. Natl. Acad. Sci. U.S. 85, 9724 (1988).
  298. Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to EGF receptor. E. Aboud-Pirak, E. Hurwitz, F. Bellot, J. Schlessinger and M. Sela, Proc. Natl. Acad. Sci. U.S. 86, 3778 (1989).
  299. The effect of anti-alpha-fetoprotein-adriamycin conjugate on a human hepatoma. E. Galun, D. Shouval, R. Adler, M. Shahaar, M. Wilchek, E. Hurwitz and M. Sela, Hepatology 11, 578 (1990).
  300. A conjugate of 5-fluorouridine-poly-(l-lysine) and an antibody reactive with human colon carcinoma. E. Hurwitz, I. Stancovski, M. Wilchek, D. Shouval, H. Takahashi, J.R. Wands and M. Sela, Bioconjugate Chemistry 1, 285 (1990).
  301. Indirect immunotargeting of Cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system. B. Schechter, R. Arnon, M. Wilchek, J. Schlessinger, E. Hurwitz, E. Aboud-Pirak and M. Sela, Intl. J. Cancer 48, 167 (1991).
  302. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. M.B. Bornstein, A. Miller, S. Slagle, M. Weitzman, E. Drexler, M. Keilson, V. Spada, W. Weiss, S. Appel, L. Rolak, Y. Harati, S. Brown, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela, Neurology 41, 533 (1991).
  303. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. I. Stancovski, E. Hurwitz, O. Leitner, A. Ullrich, Y. Yarden and M. Sela, Proc. Natl. Acad. Sci. U.S. 88, 8691 (1991).
  304. Cross reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. D. Teitelbaum, R. Aharoni, M. Sela and R. Arnon, Proc. Natl. Acad. Sci. U.S. 88, 9528 (1991).
  305. Direct binding of a synthetic multichain polypeptide to class II major histocompatibility complex molecules on antigen-presenting cells and stimulation of a specific T-cell line require processing of the polypeptide. E. Zisman, M. Sela and E. Mozes, Proc. Natl. Acad. Sci. U.S. 88, 9738 (1991).
  306. Synthetic copolymer 1 inhibits human T cell lines specific for myelin basic protein. D. Teitelbaum, R. Milo, R. Arnon and M. Sela, Proc. Natl. Acad. Sci. U.S. 89, 137 (1992).
  307. Signal transduction by the Neu/ErbB-2 receptor: A potential target for anti-tumor therapy. I. Stancovski, E. Peles, R. Ben Levy, R. Lemprecht, Z. Kelman, R. Goldman-Michael, E. Hurwitz, S. Bacus, M. Sela and Y. Yarden, J. Steroid Biochem. Molec. Biol. 43, 95 (1992).
  308. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. S.S. Bacus, I. Stancovski, E. Huberman, D. Chin, E. Hurwitz, G.B. Mills, A. Ullrich, M. Sela and Y. Yarden, Cancer Research 52, 2580 (1992).
  309. Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. E. Hurwitz, R. Adler, D. Shouval, H. Takahashi, J.R. Wands and M. Sela, Cancer Immunol. Immunotherapy 35, 186 (1992).
  310. Structural origin of the immunological diversity of two closely related tetrapeptides: CIDNP study of TyrTyrGluGlu and TyrGluTyrGlu epitopes. K.A. Muszkat, B. Schechter and M. Sela, Mol. Immunol. 29, 1049 (1992).
  311. catELISA :- A facile general route to catalytic antibodies. D.S. Tawfik, B.S. Green, R. Chap, M. Sela and Z. Eshhar, Proc. Natl. Acad. Sci. U.S.A. 90, 373 (1993).
  312. Ia-antigen-T cell interactions for a thymus-independent antigen composed of D-amino acids. E. Zisman, M. Dayan, M. Sela and E.Mozes, Proc. Natl. Acad. Sci., U.S.A. 90, 994 (1993).
  313. Aromatic side-chain interactions as the origin of immunological diversity in the TyrTyrGluGlu and TyrGluTyrGlu epitopes: NMR and fluorescence evidence. K.A. Muszkat, B. Schechter and M. Sela, Internat. Immunol. 5, 591 (1993).
  314. Targeting of T lymphocytes to Neu/HER2- expressing cells using chimeric single chain Fv receptors. I. Stancovski, D.G. Schindler, T. Waks, Y. Yarden, M. Sela and Z. Eshhar, J. Immunol. 151, 6577 (1993).
  315. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Y. Katz-Levy, S.L. Kirshner, M. Sela and E. Mozes, Proc. Natl. Acad. Sci. U.S.A. 90, 7000 (1993).
  316. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. S.S. Bacus, A.V. Gudkov, C.R. Zelnick, D. Chin, R. Stern, I. Stancovski, E. Peles, N. Ben-Baruch, H. Farbstein, R. Lupu, D. Wen, M. Sela and Y. Yarden, Cancer Research 53, 5251 (1993).
  317. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. M. Fridkis-Hareli, D. Teitelbaum, E. Gurevich, I. Pecht, H. Brautbar, O. Joong Kwon, T. Brenner, R. Arnon and M. Sela, Proc. Natl. Acad. Sci. USA 91, 4872 (1994).
  318. Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)-A--L. E. Zisman, M. Sela, A. Ben-Nun and E. Mozes, Eur. J. Immunol. 24, 2497 (1994).
  319. Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen- presenting cells. M. Fridkis-Hareli, D. Teitelbaum, R. Arnon and M. Sela, Cellular Immunol. 163, 229 (1995).
  320. Binding of peptides of the human acetylcholine receptor a-subunit to HLA class II of patients with myasthenia gravis. E. Zisman, Ch. Brautbar, M. Sela, O. Abramsky, S. Battat, S.L. Kirshner, Y. Katz-Levy, M. Dayan and E. Mozes, Human Immunology 44, 121 (1995).
  321. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition state analog. Is there a linkage to autoimmunity? D.S. Tawfik, R. Chap, B.S. Green, M. Sela and Z. Eshhar, Proc. Natl. Acad. Sci. U.S. 92, 2145 (1995).
  322. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. E. Hurwitz, I. Stancovski, M. Sela and Y. Yarden, Proc. Natl. Acad. Sci, U.S. 92, 3353 (1995).
  323. Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice R. Adler, E. Hurwitz,J.R. Wands, M. Sela and D. Shouval, Hepatology 22, 1482 (1995).
  324. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. D. Teitelbaum, M. Fridkis-Hareli, R. Arnon and M. Sela, J. Neuroimmunology 64, 209 (1996).
  325. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. G. Levkowitz, L.N. Klapper, E. Tzahar, A. Freywald, M. Sela and Y. Yarden, Oncogene 12, 1117 (1996).
  326. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B.J. Ratzkin, M. Sela and Y. Yarden, EMBO J. 15, 2452 (1996).
  327. A synthetic random basic copolymer with promiscuous binding to class II MHC molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. P.G. Schlegel, R. Aharoni, Y. Chen, J. Chen, D. Teitelbaum, R. Arnon, M. Sela and N.J. Chao, Proc. Natl. Acad. Sci. USA 93, 5061 (1996).
  328. Peptide analogs to pathogenic epitopes of the human acetylcholine receptor a-subunit as potential modulators of myasthenia gravis. E. Zisman, Y. Katz-Levy, M. Dayan, S.L. Kirshner, M. Paas-Rosner, A. Karni, O. Abramsky, C. Brautbar, M. Fridkin, M. Sela and E. Mozes, Proc. Natl. Acad. Sci. USA 93, 4492 (1996).
  329. Altered peptide ligands of a myasthenogenic epitope as modulators of specific T cell responses. S.L. Kirshner, E. Zisman, M. Fridkin, M. Sela and E. Mozes, Scandinavian J. Immunol. 44, 512 (1996).
  330. Binding of copolymer 1 and myelin basic protein leads to clustering of class II major histocompatibility complex molecules on antigen-presenting cells. M. Fridkis-Hareli, D. Teitelbaum, I.Pecht, R. Arnon and M. Sela, Int. Immunol. 9, 925 (1997).
  331. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/Her 2 blocks crosstalk with growth factor receptors. L.N. Klapper, N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, Y. Yarden and M. Sela, Oncogene 14, 2099 (1997).
  332. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. R. Aharoni, P.G. Schlegel, D. Teitelbaum, O. Reikhel-Karpov, Y. Chen, R. Arnon, M. Sela and N.J. Chao, Immunology Letters 58, 79 (1997).
  333. Reactivity of T cells from seronegative patients of myasthenia gravis to T cell epitopes of the human acetylcholine receptor. A. Karni, E. Zisman, Y. Katz-Levy, M. Paas-Rozner, M. Dayan, C. Brautbar, O. Abramsky, M. Sela and E. Mozes, Neurology 48, 1638 (1997).
  334. A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Y. Katz-Levy, M. Paas-Rozner, S. Kirshner, M. Dayan, E. Zisman, M. Fridkin, I. Wirguin, M. Sela and E. Mozes, Proc. Natl. Acad. Sci. U.S. 94, 3200 (1997).
  335. Copolymer 1 induces T-cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. R.Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Proc. Natl. Acad. Sci. USA. 94, 10821 (1997).
  336. Bivalence of EGF-like ligands drives the ErbB signaling network. E. Tzahar, R. Pinkas-Kramarski, J.D. Moyer, L.N. Klapper, I Alroy, G. Levkowitz, M. Shelly, S. Henis, M. Eisenstein, B.J. Ratzkin, M. Sela, G.C. Andrews and Y. Yarden, EMBO J. 16, 4938 (1997).
  337. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. R. Pinkas-Kramarski, A.E.G. Lenferink, S.S. Bacus, L. Lyass, M.L.M. van de Poll, L.N. Klapper, E. Tzahar, M. Sela, E. J.J. van Zoelen and Y. Yarden, Oncogene 16, 1249 (1998).
  338. Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis. Y. Katz-Levy, M. Dayan, I. Wirguin, M. Fridkin, M. Sela and E. Mozes, J. Neuroimmunology 85, 78 (1998).
  339. Differential endocytic routing of homo- and hetero- dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. A. E.G. Lenferink, R. Pinkas-Kramarski, M. L.M. van de Poll, M.J.H. van Vugt, L. N. Klapper, E. Tzahar, H. Waterman, M. Sela, E. J.J. van Zoelen and Y. Yarden, EMBO Journal 17, 3385 (1998).
  340. Bystander suppression of experimental autoimmune encephalomyelitis by T-cell lines and clones of the Th2 type induced by copolymer 1. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, J. Neuroimmunology 91, 135 (1998).
  341. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity but not tyrosine phosphorylation induced by myasthenogenic T cell epitopes. A. Faber-Elmann, M. Paas-Rozner, M. Sela and E. Mozes, Proc. Natl. Acad. Sci. U.S. 95, 14320 (1998).
  342. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to the MHC blocking R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela, Proc. Natl. Acad. Sci. U.S. 96, 634 (1999).
  343. Binding motifs of copolymer 1 to multiple sclerosis - and rheumatoid arthritis- associated HLA-DR molecules.
    M. Fridkis-Hareli, J.M. Neveu, R.A. Robinson, W.S. Lane, L. Gauthier, K.W. Wucherpfennig, M. Sela and J. L. Strominger, J.Immunol. 162, 4697 (1999).
  344. Binding of random copolymers of three amino acids to class II MHC molecules. M. Fridkis-Hareli, R. Aharoni, D. Teitelbaum, R. Arnon, M. Sela and J.L. Strominger, International Immunology, 11, 635 (1999).
  345. Immunomodulation of experimental autoimmune encephalomyelitis by oral admini- stration of copolymer 1. D. Teitelbaum, R. Arnon and M. Sela, Proc. Natl. Acad. Sci, U.S. 96, 3842 (1999).
  346. The ErbB-2/HER 2 oncoprotein of human carcinomas may function solely as a shared co-receptor for multiple stroma-derived growth factors. L.N. Klapper, S. Glathe, N.E. Hynes, G.C. Andrews, M. Sela and M. Yarden, Proc. Natl. Acad. Sci. U.S. 96, 4995 (1999).
  347. Immunomodulation of myasthenia gravis associated autoimmune responses by an altered peptide-ligand: mechanisms of action. M. Paas-Rozner, A. Faber-Elmann, M. Sela and E. Mozes, Satellite Meet. on Myasthenia Gravis, November 1998, Mysore, India, "MG Workshop Proceedings," P. Christadoss, ed., Narosa Publ. House, 2000, p. 182.
  348. An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1, induced in vivo by a myasthenogenic T cell epitope. A. Faber-Elmann, V. Grabovsky, M. Dayan, M. Sela, R. Alon and E. Mozes, FASEB J. 15, 187 (2001).
  349. Inhibition of tumor growth by polyethylene glycol derivatives of anti-ErbB2 antibodies. E. Hurwitz, L.N. Klapper, M. Wilchek, Y. Yarden and M. Sela, Cancer Immunol. Immunotherapy 49, 226 (2000).
  350. c-Cbl is a suppressor of the Neu oncogene. G. Levkowitz, S. Oved, L.N. Klapper, S. Lair, M. Sela and Y. Yarden, J. Biol. Chem. 275, 35532 (2000).
  351. Cytokine profile and T cell adhesiveness to endothelial selections: In vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. A. Faber-Elmann, V. Grabovsky, M. Dayan, M. Sela, R. Alon and E. Mozes, Intl. Immunol.
  352. Oral administration of a dual analog of two myasthenogenic T cell epitopes down regulates experimental autoimmune myasthenia gravis in mice. M. Paas-Rozner, M. Dayan, Y. Paas, J.-P. Changeux, I. Wirguin, M. Sela and E. Mozes. Proc. Natl. Acad. Sci. U.S. 97, 2168 (2000).
  353. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. T. Brenner, R. Arnon, M. Sela, O . Abramsky, Z. Meiner, R. Riven-Kreitman, N. Tarcik and D. Teitelbaum. J. Neuroimmunology 115, 152 (2001).
  354. T-Cell immunity to Copolymer-1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. J. Kipnis, E. Yoles, Z. Porat, F. Mor, M. Sela, I.R. Cohen and M. Schwartz, Proc. Natl. Acad. Sci. U.S. 97, 7446 (2000).
  355. Tumor-inhibitory antibodies to HER2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER2. L.N. Klapper, H. Waterman, M. Sela and Y. Yarden, Cancer Research 60, 3384 (2000).
  356. An altered peptide ligand immunomodulates specific myasthenogenic T cell responses via immunosuppressive cytokines. M. Paas-Rozner, M. Sela and . Mozes, J. Neuroimmunology.
  357. Specific Th2 cells accumulate in the central nervous system of mice protected against EAE by copolymer 1. R. Aharoni, D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela and R. Arnon, Proc. Natl. Acad. Sci. U.S. 97, 11472 (2000).
  358. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. N. Vaisman, A. Nissim, L.N. Klapper, B. Tirosh, Y. Yarden and M. Sela, Immunology Letters 75, 61 (2000).
  359. Copolymer 1 inhibits manifestations of graft rejection. R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela, Transplantation.

 Review Articles, Books, Lectures, Chapters

  1. Synthesis and chemical properties of poly-a-amino acids. E. Katchalski and M. Sela, Advances in Protein Chemistry 13, 243-492 (1958).
  2. Biological properties of poly-a-amino acids. M. Sela and E. Katchalski, Advances in Protein Chemistry 14, 391-477 (1959).
  3. Some contributions of the study of synthetic polypeptides to the understanding of the chemical basis of antigenicity. M. Sela, in M.A. Stahmann, ed., "Polyamino Acids, Polypeptides and Proteins", University of Wisconsin Press, Madison, Wisconsin, p. 347 (1962).
  4. Synthetische polypeptide als protein-modelle. M. Sela, Angew. Chem. 74, 659 (1962); English Ed. 1, 411 (1962).
  5. New perspectives in biology. M. Sela, Editor, Elsevier Publishing Company, Amsterdam, 1964.
  6. Synthetic polypeptide antigens. M. Sela, in M. Sela, ed., "New Perspectives in Biology", Elsevier Publishing Company, Amsterdam, p. 225 (1964).
  7. Emploi des polypeptides synthetiques dans l'etude de l'antigenicite. M. Sela, Cinquantenaire de la Societe de Chimie Biologique Francaise. Conferences et Rapports, p. 131 (final edition, p. 443) (1964); Bull. Soc. Chim. Biol. 46, 1685 (1964).
  8. Polyamino acids as protein models. E. Katchalski, M. Sela, H.I. Silman and A. Berger, in H. Neurath, ed. "The Proteins", Academic Press, Inc., New York, Vol. 2, pp. 405-602 (1964).
  9. Polyamino acids. H.I. Silman, M. Sela and E. Katchalski, Atomlight 40, 9 (1964).
  10. Nucleoside-specific antibodies elicited by synthetic antigens. M. Sela and H. Ungar-Waron, Fed. Proc. 24, 1438 (1965).
  11. Use of synthetic polypeptides and peptidyl proteins in studies of immunological tolerance. M. Sela, Proc. intern. Symp. on Immunological Tolerance (Locarno), Internat. Arch. Allergy Appl. Immunol. 27, 363 (1965).
  12. Chemical basis of antigenicity. M. Sela, Proc. Israel Acad. Sciences and Humanities Vol. 1, No. 9 (1965).
  13. Immunological studies with synthetic polypeptides. M. Sela, Advances in Immunology 5, 29-129 (1966).
  14. Chemical studies of the combining sites of antibodies. M. Sela, Proc. Roy. Soc. B. 166, 188 (1966).
  15. Preparation of synthetic polypeptides as antigens. M. Sela and S. Fuchs, in M.W. Chase and C.A. Williams, eds., "Methods in Immunology and Immunochemistry", Academic Press, Inc., New York, Vol. l, p. 167 (1967).
  16. Preparation of nucleoside conjugates of synthetic polypeptides. M. Sela and S. Fuchs, in M.W. Chase and C.A. Williams, eds., "Methods in Immunology and Immunochemistry," Academic Press, Inc., New York, Vol. 1, p. 185 (1967).
  17. Biological properties of poly-a-amino acids. H.I. Silman and M. Sela, in G.D. Fasman, Ed., "Poly-a-amino acids as protein models for conformational studies", Marcel Dekker, Inc., New York, pp. 605-673 (1967).
  18. Reaction with N-carboxy-a-amino acid anhydrides. M. Sela and R. Arnon, in C.H.W. Hirs, ed., "Enzyme Structure", Methods in Enzymology, Vol. 11, Academic Press, Inc., New York, p. 580 (1967).
  19. Synthetic antigens. M. Sela, Science Journal, Vol. 3, No. 8, p. 61 (1967).
  20. Use of synthetic polypeptides in studies on the control of antibody formation. M. Sela, in Nobel Symposium III, on "Gamma Globulins", J. Killander (ed.), Almqvist and Wiksell, Stockholm, p. 455 (1967).
  21. Antibodies to sequential and conformational determinants. M. Sela, B. Schechter, I. Schechter and F. Borek, Cold Spring Harbor Symposia on Quantitative Biology, 32, 537 (1967).
  22. Synthetic antigens. M. Sela, in B. Rose, M. Richter, A. Sehon and A.W. Frankland, eds., "Allergology", Excerpta Medica Foundation, Amsterdam, p. 175 (1968).
  23. Preparation of nucleoside-specific synthetic antigens. M. Sela and H. Ungar-Waron, in L. Grossman and K. Moldave, eds., "Nucleic Acids", Methods in Enzymology, Vol. 12, Part B, Academic Press, Inc., New York, p. 900 (1968).
  24. Immunogenic synthetic polypeptides; Some low molecular weight compounds with immunogenic properties; Immunogenic peptides and their derivatives; Immunogenic conjugates of synthetic polypeptides. F. Borek and M. Sela, Handbook of Biochemistry (Ed. H.A. Sober) p. K-22, The Chemical Rubber Co., Cleveland, 1968.
  25. Antibodies: shape, homogeneity and valency. M. Sela, FEBS Letters 1, 83 (1968).
  26. Antigens and antigenicity. M. Sela, Naturwiss 56, 206 (1969).
  27. Topics in basic immunology. M. Sela (ed.), Special Issue of Israel J. Med. Sci. 5, No. 2 (1969).
  28. Antigenicity: Some molecular aspects. M. Sela, Science 166, 1365 (1969).
  29. Topics in basic immunology. M. Sela and M. Prywes, eds., Academic Press, New York 1969.
  30. Discussions. M. Sela, in M. Landy and W. Braun (eds.), "Immunological Tolerance", Academic Press, New York, 1969.
  31. Structure and specificity of synthetic polypeptide antigens. M. Sela, Ann. N.Y. Acad. Sci. 169, 23 (1970).
  32. On the combining sites of antibodies to defined determinants. M. Sela, I. Schechter, B. Schechter and A. Conway-Jacobs, in "Homologies in Enzymes and Metabolic Pathways and Metabolic Alterations in Cancer", Ed. W.J. Whelan and J. Schultz, Miami Winter Symposia, Vol. 1, North-Holland Publishing Co., Amsterdam, 1970, p. 382.
  33. Molekulare Gesichtspunkte der Antigenitat. M. Sela, Umschau 70, 501 (1970).
  34. Conversion with polynucleotides of a genetically controlled low immune response to a high response in mice toward a synthetic polypeptide antigen. E.Mozes, G.M. Shearer, M. Sela and W. Braun. "Biological Effects of Polynucleotides", in R.F. Beers and W. Braun, eds., Springer Verlag, New York, p. 162 (1970).
  35. Effect of antigenic structure on antibody biosynthesis. M. Sela, Ann. N.Y. Sci. 190, 181 (1971).
  36. Detection of proteins with chemically modified bacteriophages. M. Sela and J. Haimovich, Protides of the Biological Fluids, Vol. 18, ed. H. Peeters, Pergamon Press, London, p. 391 (1971).
  37. Cellular basis of the genetic control of immune response. G.M. Shearer, E. Mozes and M. Sela, Proceedings First International Congress of Immunology, Washington, August 1971, Progress in Immunology (ed. B. Amos), Academic Press, New York, p. 509 (1971).
  38. Molecular genetics of antibody formation. M. Sela, FEBS Letters 19, 181 (1971).
  39. Reaction with N-carboxy-a-amino acid anhydrides. M. Sela and R. Arnon, in C.H.W. Hirs and S.N. Timasheff, eds., Methods in Enzymology, Vol. 25, Part B, Academic Press, Inc., New York, p. 553 (1972).
  40. Highly sensitive immunoassay of proteins and other compounds with bacteriophage. M. Sela, Triangle 11, 61 (1972).
  41. Discussions. M. Sela, in H.O. McDevitt and M. Landy (eds.), "Genetic Control of Immune Responsiveness", Acad. Press, New York, 1972.
  42. Genetic control and immunity. E. Mozes, G.M. Shearer and M. Sela, in Immunity in Viral and Rickettsial Diseases, ed. A. Kohn and M.A. Klingberg, Plenum, New York, p. 145 (1972).
  43. Structural features of antigens. M. Sela, in R.E. Ballieux, M. Gruber and H.G. Seijen, eds., "Immunoglobulins: Cell Bound Receptors and Humoral Antibodies", FEBS Proc. 8th Meeting, Amsterdam, August 1972, Vol. 26, p. 87, North-Holland/American Elsevier, Amsterdam and New York.
  44. Rolul Conformatiei in Antigenicitate. M. Sela, Microbiologia, Parazitologia, Epidemiologia 17, 293 (1972).
  45. Reflexions sur la Recherche Scientifique dans un petit pays. M. Sela, Science Israel, No. 1, p. 13 (1972).
  46. Antigen-antibody relationship. M. Sela, in "From Theoretical Physics to Biology", ed. M. Marois, p. 307 (1973), S. Karger, Basel, Proc. 3rd Intern. Conf., Versailles, June 21-26, 1971.
  47. The preparations of synthetic antigens. M. Sela and S. Fuchs, in Handbook of Experimental Immunology, 2nd Edition, Ed. D.M. Weir, Blackwell Scientific Publications, Oxford, Chap. 1 (1973).
  48. Immunoadsorbents. S. Fuchs and M. Sela, in Handbook of Experimental Immunology, 2nd Edition, Ed. D.M. Weir, Blackwell Scientific Publications, Oxford, Chap. 11 (1973).
  49. Antigen design and immune response. M. Sela, Harvey Lectures 1971-72, 67, 213 (1973).
  50. Antigen Design and Immune Responsiveness. M. Sela, Behring Institute Mitteilungen 53, 1 (1973).
  51. The Antigens, Volume 1. M. Sela (ed.), Academic Press, New York, 1973.
  52. Vaccins Synthetiques - Un Reve ou Une Realite? M. Sela, Bull. Inst. Pasteur 72, 73 (1974). Included in "La Microbiologie Cent Ans Apres Pasteur, Bilan et Perspectives."
  53. The ordered polymer (Pro-Gly-Pro)n - an immunological model for collagen. S. Fuchs, A. Maoz and M. Sela, Israel J. Chem. 12, 681 (1974).
  54. Selected highlights in immunological research in the last decade. M. Sela, FEBS Letters (Special Issue for the 10th Anniversary of FEBS) 40, 585 (1974).
  55. Genetic control of immune response. Introduction. M. Sela, Proceedings 2nd Internat. Congr. Immunol., Brighton, July 1974, Progress in Immunology II, Volume 3, A.S.P. Biological and Medical Press, North-Holland Division, Amsterdam, p. 179 (1974).
  56. The Antigens, Volume 2. M. Sela (ed.), Academic Press, New York, 1974.
  57. Synthetic antigens and recent progress in immunology. M. Sela, in "Peptides, Polypeptides and Proteins", Proc. Rehovot Symp. on Poly(Amino Acids), Polypeptides and their Biological Implications, Israel, May 1974, Eds. E.R. Blout, F.A. Bovey and N. Lotan, p. 495, John Wiley, New York, 1974.
  58. The role of antigenic structure in B lymphocyte activation. M. Sela and E. Mozes, Transplantation Reviews 23, 189 (1975).
  59. Antigen design and immunological recognition. M. Sela, in "Stability and Origin of Biological Information", Proc. 1st Aharon Katzir-Katchalsky Conf., Rehovot June 1973, Ed. I.R. Miller, p. 173, John Wiley, New York, 1975.
  60. Synthetic vaccines of the future. M. Sela, in Antiviral Mechanisms, Perspectives in Virology, Ed. M. Pollard, Vol. 9, p. 91 (1975), Academic Press, New York.
  61. The Antigens, Volume 3. M. Sela (ed.), Academic Press, New York, 1975.
  62. Synthetic approaches to some applied aspects of antigenicity. M. Sela, in "Critical Factors in Cancer Immunology", J. Schultz and R.C. Leif, Eds., Miami Winter Symposia, Vol. 10, Academic Press, New York, 1975, p. 23.
  63. Antigen design as a tool for probing into the nature of immunological phenomena. M. Sela, Proc. Robert Welch Foundation, Conferences on Chemical Research. XVIII, Immunochemistry, W.O. Milligan, Ed., p. 201, 1975, Houston, Texas.
  64. Conformational changes induced in areas of antibody distal from its combining sites - possible significance for reaction with receptor. M. Sela, in "Membrane Receptors of Lymphocytes", M. Seligmann, J.L. Preud'homme and F.M. Kourilsky, Eds., North Holland Publishing Co., Amsterdam, 1975, p. 373.
  65. Reflections on the Impact of Lymphocyte Membrane Research. M. Sela, in "Membrane Receptors of Lymphocytes", M. Seligmann, J.L. Preud'homme and F.M. Kourilsky, Eds., North Holland Publishing Co., Amsterdam, 1975, p. 459.
  66. Discussions. M. Sela, in D.H. Katz and B. Benacerraf (eds.) "The Role of the Products of the Histocompatibility Gene Complex in Immune Responses", Academic Press, New York, 1976.
  67. The Antigens, Volume 4. M. Sela (ed.), Academic Press, New York, 1977.
  68. Synthetic approaches to the immunology of the future. M. Sela, in "Progress in Immunology III" Eds. T.E. Mandel, C. Cheers, C.S. Hosking, I.F.C. McKenzie and G.J.V. Nossal, Australian Academy of Science, Canberra, 1977, p. 720.
  69. Chemically modified bacteriophages. J. Haimovich and M. Sela, in "Methods in Immunology and Immunochemistry", Eds. M.W. Chase and C.A. Williams, Academic Press, Inc. New York, Vol. 4, 1977, p. 386.
  70. Synthetic approaches to applied medical aspects of immunology. M. Sela Asian Journal of Infectious Diseases, 1, 97 (1977).
  71. Non-radioactive immunoassays for the determination of drugs and other antigens. J. Haimovich and M. Sela, in Hirtz and Garrett, "Drug Fate and Metabolism." Methods and Techniques, Vol. 2, p. 257, Marcel Dekker, Inc., New York, 1978.
  72. Experimental allergic encephalomyelitis. M. Sela, D. Teitelbaum and R. Arnon. The Menarini Series on Immunopathology. Vol. 1. First Symposium on Organ Specific Autoimmunity, Cremona, Italy (June 1977), Eds. P.A. Miescher, Schwabe Co., Basel, p. 9 (1978).
  73. Synthetic antigens with peptide determinants of defined sequence. M. Sela, M. Schwartz and E. Mozes, in C.H. Li, editor, "Versatility of Proteins", Academic Press, New York, 1978, p. 269.
  74. The role of non-specific immunity in the prevention and treatment of cancer. M. Sela, ed., Pontificiae Academiae Scientiarum Scripta Varia, Vol. 43, 1979.
  75. Use of antibodies for delivery of chemotherapeutic drugs. M. Sela, E. Hurwitz and R. Maron, in "The Role of Non-specific Immunity in the Prevention and Treatment of Cancer", Pontificiae Academiae Scientiarum Scripta Varia, Vol. 43, M. Sela, Ed., p. 481 (1979).
  76. The challenge of the combined use of synthetic antigens and synthetic adjuvants. M. Sela and E. Mozes, in L. Chedid, editor "Immunostimulants", Springer Seminars in Immunopathology, 2 119 (1979); as well as in L. Chedid, P.A. Miescher and J.J. Mueller-Eberhard editors, "Immunostimulation", Springer-Verlag, Berlin, p. 215, 1980.
  77. An approach to the vaccines of the future through chemical synthesis. M. Sela, Inauguration Symposium on "Current Trends in Immunology and Genetics and Their Implications for Parasitic Diseases", Nairobi, p. 55 (1979).
  78. Synthetic approaches to immunology in the future. M. Sela, in "Molecular Mechanisms of Biological Recognition". M. Balaban, ed. p. 21, Elsevier/North Holland, Amsterdam, 1979.
  79. The Antigens, Vol. 5. M. Sela (ed.), Academic Press, New York, 1979.
  80. Antibodies as carriers for oncostatic materials. R. Arnon, E. Hurwitz and M. Sela, Recent Results in Cancer Research, Vol. 75, G. Mathe and F.M. Muggia, editors, p. 236 (1980), Springer Verlag, Heidelberg.
  81. Chemical synthesis for understanding of immune response phenomena and for their medical application. M. Sela (Mexican Symposium), in "Molecules, Cells, and Parasites in Immunology", C. Larralde, K. Willms, L. Ortiz-Ortiz and M. Sela, Editors, Academic Press, New York, 1980, p. 215.
  82. Antigens and antibodies: Structural and functional relationships. M. Sela, Advances in Allergology and Applied Immunology, ed. A. Oehling, E. Mathov, I. Glazer and C. Arbesman, Proc. X Internat. Congress Allergology (Jerusalem 1979). Pergamon Press, Oxford, p. 3, 1980.
  83. Molecules, Cells and Parasites in Immunology, C. Larralde, K. Willms, L. Ortiz-Ortiz and M. Sela, Editors, Academic Press, New York, 1980.
  84. Summary: Genetic regulation of immune responsiveness. M. Sela, "Immunology 80", Progress in Immunology IV, M. Fougereau and J. Dausset, editors, p. 496 (1980), Academic Press, London.
  85. Antiviral antibodies obtained with aqueous solution of a synthetic antigen. M. Sela and R. Arnon, in "New Developments with Human and Veterinary Vaccines", M.A. Klingberg and A. Kohn, eds., p. 315, Alan R. Liss, Inc. New York, 1980.
  86. Einstein and the Jewish Question. M. Sela, Epistemologia III, Numero Speciale, p. 253 (1980).
  87. Synthetic antigens - An insight into the specificity of B and T cells. E. Mozes and M. Sela, "The Immune System 2. The Present", p. 99, Festchrift in honor of Niels Kaj Jerne on the occasion of his 70th birthday, Ch. M. Steinberg and I. Lefkovitz, eds. 1981, S. Karger Basel.
  88. Immunological approaches to the vaccines of the future. M. Sela and R. Arnon, in "Biological Products for Viral Diseases", P.A. Bachmann, ed., Taylor and Francis Ltd., London, 1981, p. 21.
  89. From synthetic antigens to synthetic vaccines. M. Sela, Immunology Today 2, 148 (1981).
  90. In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumour antibodies. R. Arnon and M. Sela, Imm Rev. 62, 5 (1982).
  91. Basic research and practical applications in a multidisciplinary institute. M. Sela, Proc. of Lambo Foundation Inaugural Lectures, Abeokuta (Nigeria), November 1982.
  92. The Antigens, Vol. 6. M. Sela (ed.), Academic Press, New York, 1982.
  93. Targeted chemotherapy: drugs conjugated to anti-tumor antibodies. R. Arnon and M. Sela, Cancer Surveys 1, 429 (1982).
  94. The consequences of new approaches in parasitological research. R. Arnon and M. Sela, in "Parasitology, a Global Perspective", K.S. Warren and J.Z. Bowers, eds., p. 246 (1983), Springer Verlag, New York.
  95. From synthetic antigens to synthetic vaccines. M. Sela, Biopolymers 22, 415 (1983).
  96. Otto Westphal. On the occasion of his 70th birthday. M. Sela, Europ. J. Immunol. 13, XIII (1983).
  97. Antigenes et vaccins synthetiques. R. Arnon and M. Sela, La Recherche 14, 346 (1983).
  98. Discussions, "Science and the Modern World", Part II, Proc. Symposium Plenary Session, 11-13 October 1978, Pontificiae Academiae Scientiarum Scripta Varia 49, 45, 49, 87, 113 (1983).
  99. Effect of a conjugate of daunomycin and purified polyclonal or monoclonal antibodies to rat-a-fetoprotein on the growth of a-fetoprotein-producing tumor cells. Y. Tsukada, E. Hurwitz, R. Kashi, M. Sela, N. Hibi, A. Hara and H. Hirai, Ann. N.Y. Acad. Sci. 417, 262 (1983). "Oncodevelopmental Biology and Medicine", eds. E. Alpert and H. Hirai.
  100. Molecular engineering of the immune system: Achievements and expectations. M. Sela, in "Progress in Immunology" V. p. 13 (1983).
  101. Protein conformation and biological function: From ribonuclease to antigens and antibodies. M. Sela, in "The Impact of Protein Chemistry on the Biomedical Sciences" A.N. Schechter, A. Dean and R.F. Goldberger, eds., p. 177, 1984, Academic Press, New York.
  102. Synthetic approaches to vaccination against cholera toxin. M. Sela, C.O. Jacob and R. Arnon, in "Modern Approaches to Vaccines", R.M. Chanock and R.A. Lerner, eds., Cold Spring Harbor Symp. Quant. Biol. p. 87, 1984.
  103. Synthetic antigens and vaccines. M. Sela and R. Arnon, Interdisciplinary Science Reviews 9, 271 (1984).
  104. Clinical trials of copolymer 1 in multiple sclerosis. M.B. Bornstein, A.I. Miller, S. Slagle, R. Arnon, M. Sela and D. Teitelbaum, Ann. N.Y. Acad. Sci. 436, 366 (1984).
  105. Introduction. M. Sela, "Science in a World of Crises"(Meeting in Berlin in 1982). Miriam Balaban, ed., Balaban Publishers, Rehovot, p. 11, 1985.
  106. The immune system and its molecular engineering. M. Sela, Proc. Internat. Meet. on "Frontiers in Bioorganic Chemistry and Molecular Biology", Alma-Ata (Kazakhstan), 1984, ed. Yu. A. Ovchinnikov, p. 433, Elsevier, Amsterdam, 1985.
  107. Towards totally synthetic vaccines. M. Sela, Proc. 16th FEBS Congress (Moscow) June 1984, Ed. Yu. A. Ovchinnikov, Part C, p. 9, 1985, Science Press, Utrecht.
  108. Retrospect and prospects for synthetic vaccines: Peptides, adjuvants and conjugates. M. Sela, "Synthetic Antigens", Ann. Sclavo, p. 11, 1984, No. 2.
  109. Totally synthetic antigens as potential vaccines. M. Sela, Serono International Symposium on Immunopharmacology, Taormina March 8-10, 1984, in "Immunopharmacology", eds. P.A. Miescher, L. Bolis and M. Ghione, Raven Press, New York, p. 81, 1985.
  110. A Matter of Priorities, M. Sela, BioEssays 2, 51 (1985).
  111. Synthetic vaccines: Present and future. R. Arnon and M. Sela, Ann. Inst. Pasteur/Immunol. 136D, 271 (1985).
  112. The Beginnings of Immunology in Israel. M. Sela, Immunology Today, "Immunology in Israel", p. 7, 1985.
  113. Synthetic peptides with antigenic specificity for bacterial toxins. M. Sela, R. Arnon and Ch.O. Jacob, in "Synthetic Peptides as Antigens", Ciba Foundation Symp. 119, R. Porter and J. Whelan, Eds. John Wiley and Sons, Chichester, p. 184 (1986).
  114. Chapter 1. Overview: Antigens. M. Sela, in "Handbook of Experimental Immunology. 1. Immunochemistry" ed. D.M. Weir, p. 1.1, Blackwell Scientific Publications, Oxford, Fourth Edition, 1986.
  115. Chapter 2. Preparation of synthetic antigens. M. Sela and S. Fuchs, in "Handbook of Experimental Immunology. 1. Immunochemistry" ed. D.M. Weir, p. 2.1, Blackwell Scientific Publications, Oxford, Fourth Edition, 1986.
  116. Citation Classic: "Sela M., Fuchs, S. and Arnon R. Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine. Biochemical J. 85: 223-35, 1962." Current Contents, Number 37, Sept. 15, 1986.
  117. Conjugates of antibodies with cytotoxic drugs. M. Sela and H. Hurwitz, in "Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer", ed. C.W. Vogel, Oxford University Press, N.Y. 1987, p.189.
  118. From synthetic polypeptides to synthetic vaccines - antigenic structure and function. M. Sela and R. Arnon, in "Immunogenicity of Protein Antigens: Repertoire and Regulation", eds. E.E. Sercarz and J.A. Berzofsky, CRC Press, Volume I, p. 5 (1987).
  119. Choice of carrier. M. Sela, in "Synthetic Vaccines", ed. R. Arnon, CRC Press, Volume I, p. 83 (1987).
  120. Ephraim Katzir - My Mentor and Friend. M. Sela, Biopolymers 26, Supplement, p. V (1987).
  121. A peripatetic and personal view of molecular immunology for one third of the century. M. Sela, Ann. Rev. Immunol. 5, 1 (1987).
  122. Citation Classic: "McDevitt H.O. and Sela M. Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J. Exp. Med. 122, 517-31, 1965." Current Contents, Number 9, March 2, 1987.
  123. Alpha-fetoprotein: its diagnostic specificity and therapeutic use of its antibody. H. Hirai, H. Taga, H. Kaneda, H. Ishizuka, Y. Kamata, T. Koji, N. Ishii, Y. Tsukada, E. Hurwitz, M. Sela, K. Hara, K. Katoh, Y. Umemoto and T. Shima, in "Human Tumor Markers", eds. Cimino, Birkmayer, Klavins, Pimentel and Salvatore, Publisher Walter de Gruyter and Co., Berlin, 1987, p. 181.
  124. The Antigens, Vol. 7, M. Sela (ed.), Academic Press, 1987.
  125. Clinical trials of a synthetic polypeptide (Copolymer 1) for the treatment of multiple sclerosis. M.B. Bornstein, A.I. Miller, S. Slagle, V. Spada, R. Arnon, M. Sela and D. Teitelbaum, Proc. 25th Anniv. Symp. of the Belgian Research Group for Multiple Sclerosis, Brussels.
  126. Clinical experience with Cop-1 in multiple sclerosis. M.B. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, S. Wassertheil-Smoller, V. Spada, W. Weiss, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela, Neurology 38, Suppl. 2, 66 (1988).
  127. Some highlights of current immunology research. M. Sela, Pontificiae Academiae Scientiarum Scripta Varia, Vol. 73, p. 231 (1986).
  128. From polyamino acids through immunology and allergy to synthetic vaccines and macromolecular drugs. M. Sela, in "From Allergy to Immunology", Anniversary Symposium in Honour of Professor Alain de Weck, eds. B.M. Stadler, C.H. Schneider, W.J. Pichler and C.A. Dahinden, Hans Huber Publishers, Toronto, p. 6 (1988).
  129. Clinical trial of Cop 1 in chronic-progressive multiple sclerosis. A. Miller, M. Bornstein, S. Slagle, H. Crystal, E. Drexler, M. Keilson, V. Spada, W. Weiss, M. Weitzman, S. Appel, S. Brown, L. Rolak, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela, Neurology 39, (Suppl. 1), p. 356 (1988).
  130. Immunological studies on one defined protein region - the "loop" of lysozyme. R. Arnon, M. Sela and I. Pecht, in "The Immune Response to Structurally Defined Proteins: the Lysozyme Model", eds. S.J. Smith-Gill and E.E. Sercarz, Adenine Press, Guilderland, N.Y. p. 315 (1989).
  131. Empty for now.
  132. The contribution of synthetic antigens to our understanding of the immune response. M. Sela, in "Immunology 1930-1980. Essays on the History of Immunology", Pauline M.H. Mazumdar, ed., p. 81, Wall and Thompson, Toronto, 1989.
  133. Some reflections on autoimmunity. M. Sela, Israel J. Med. Sci. 25, 697 (1989).
  134. Suppression of experimental allergic encephalomyelitis by Cop 1 - relevance to multiple sclerosis. R. Arnon, D. Teitelbaum and M. Sela, Israel J. Med. Sci. 25, 686 (1989).
  135. Clinical trials of Cop 1 in Multiple Sclerosis Murray B. Bornstein, S. Slagle, Muriel B. Weitzman, H. Crystal, Arnold E. Merriam, Sylvia Wassertheil-Smoller, Vincent Spada and W. Weiss, Aaron E. Miller, E. Drexler and Marshall Keilson, Stanley H. Appel and L. Rolak, Ruth Arnon, Michael Sela, Israel Jacobsohn and Dvora Teitelbaum. in "Handbook of Multiple Sclerosis", ed. S.D. Cook, Marcel Dekker Inc., New York, 1990, p. 469.
  136. Immunology in AIDS in 1990. M. Sela, AIDS 4 (Suppl. 1) S9 (1990).
  137. Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis. M. Sela, R. Arnon and D. Teitelbaum, Bull. Inst. Pasteur 88, 303 (1990).
  138. Antigens. M. Sela, in "Encyclopedia of Immunology", Roitt, I.M. and Delves, P. J., Eds., Academic Press, London, p. 128 (1992).
  139. Immunogens. M. Sela, in "Encyclopedia of Immunology", Roitt, I.M. and Delves, P.J., Eds., Academic Press, London, p. 813 (1992).
  140. A peripatetic and personal view of molecular immunology for one third of the century, M. Sela, in "The Excitement and Fascination of Science: Reflections by Eminent Scientists". ed. J. Lederberg, Annual Reviews Inc., Palo Alto, 1990, vol. 3, part 1 p. 1017.
  141. Vaccines of the future for infectious and autoimmune diseases. M. Sela, Kiev, Ukrainian SSR, in "Virology, Immunology and Society", V.A. Kouzminov and Y.L. Radavsky, eds., Unesco Regional Office for Science and Technology for Europe, p. 240 (1991).
  142. On science in a small country. Excerpts from a lecture at the Romanian Academy. M. Sela, Ann. Rom. Acad.
  143. A tale of two peptides, TyrTyrGluGlu and TyrGluTyrGlu, and their diverse immune behaviour. M. Sela, E. Mozes, E. Zisman, K.A. Muszkat and B. Schechter, Behring Institut Mitteilungen (Behring Institute Research Communications). 91, 54 (1992).
  144. T cell epitopes: synthetic antigens and multiple sclerosis. M. Sela, in "AIDS" Research and Human Retroviruses, ed. Robert C. Gallo, 8, 763 (1992).
  145. Drugs and vaccines in the era of new technologies. M. Sela, Proceedings Intl. Workshop on Interaction between Medicine and Engineering, The S. Neaman Institute Press, Haifa, p. 9 (1992).
  146. Synthetic approaches to vaccines for infectious and autoimmune diseases. M. Sela and R. Arnon, Vaccine, 10, 991 (1992).
  147. Polymeric drugs as immunomodulatory vaccines against multiple sclerosis. M. Sela, Proc. 34th IUPAC Intl. Symp. Macromolecules, Prague, July 1992, Makromol. Chem. Makromol. Symp. 70/71, p. 147 (1993).
  148. T Cell epitopes of synthetic antigens and of antigens related to autoimmune diseases. M. Sela, E. Zisman and E. Mozes, in "Progress in Immunology" VIII, J. Gergely et al. (Eds.), Springer-Hungarica, p. 573 (1992).
  149. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. I. Stancovski, M. Sela and Y. Yarden, in "Mammary Tumorigenesis and Malignant Progression", R. Dickson and M. Lippman (eds.), Kluwer Academic Publishers, Boston, p. 161 (1994).
  150. First general commentary M. Sela, in "The Emergence of Complexity in Mathematics, Physics, Chemistry and Biology", Pontificiae Academiae Scientiarum Scripta Varia, Vol. 89, p. 419 (1994).
  151. Peptide vaccines. R. Arnon and M. Sela, in "Immunological Recognition of Peptides in Medicine and Biology", eds. N.P. Zegers, W.J.A. Boersma and E. Claassen, TNO, Rijswijk, Holland, p. 245 (1995).
  152. Plea to vaccinate against AIDS. M. Sela, in "AIDS, Health and Human Rights", J. Mann and C. Dupuy, eds., Fondation Marcel Merieux, p. 211 (1993).
  153. Fighting cancer with monoclonals and autoimmune diseases with T cell epitopes. M. Sela, Proc. Indian Natn. Sci. Acad. B60, 443 (1994).
  154. Vaccine against AIDS? The Lancet 343, 493 (1994).
  155. The founding of the NIHAA Israeli Chapter. M. Sela and S. Fuchs, NIH AA Update 6, 13 (1994).
  156. Die Enstehung der deutsch-israelischen wissenschaftlichen Zusammenarbeit. M. Sela and D. Nickel, "Recht und Wahrheit bringen Frieden", Festschrift for Niels Hansen, Bleicher Verlag, p. 241 (1994).
  157. A personal view of molecular immunology. M. Sela, Creativity Research Journal, 7, 3-4, 327-339 (1994).
  158. Preface In Gideon Rivlin: "Guide to Organizing an International Scientific Conference", Karger, Basel, 1995, p. VIII.
  159. Discussions. M. Sela, in "The Legal and Ethical Aspects related to the Project of the Human Genome", Eds. B. Pullman and C. Romeo Casabona, Pontificiae Academiae Scientiarum Scripta Varia, 1995.
  160. Dominant epitopes and synthetic peptides in myasthenia gravis. M. Sela, S.L. Kirshner, Y. Katz-Levy, E. Zisman and E. Mozes, Israel J. Med. Sc. 31, 10 (1995).
  161. Molecular vision of B cell epitopes. M. Sela, Abstr. Intl. Symp. on "Vaccines, One Hundred Years after Louis Pasteur", Sept. 24-28, 1995, p. 75.
  162. Building bridges for peace through science. M. Sela, Symp. on "Science for Peace", UNESCO-Hebrew University Intl. School for Molecular Biology and Microbiology, December 1995, Jerusalem.
  163. Towards synthetic vaccines against autoimmune diseases. M. Sela, Symp. on "Molecular Biology and Microbiology in the Frontier of Biological and Medical Sciences", UNESCO-Hebrew University Intl. School for Molecular Biology and Microbiology, December 1995, Jerusalem.
  164. Synthetic vaccines for infectious and autoimmune diseases, M. Sela, in "Novel Strategies in Design and Production of Vaccines", S.Cohen and A. Shafferman, eds., Plenum Press, New York, p.1, 1996.
  165. The nature of antigen. M. Sela and I. Pecht, Adv. Protein Chem. 49, 287-326 (1996).
  166. New insights into the mechanism of action of Copolymer 1 in EAE and MS. R. Arnon, M. Sela and D. Teitelbaum, J. Neurology 243, Suppl. 1, S8-S13 (1996).
  167. The autoimmune reactivity of myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic; effect of Copolymer-1 on MOG-induced disease. A. Ben-Nun, I. Mendel, R. Bakimer, M. Fridkis-Hareli, D. Teitelbaum, R. Arnon, M. Sela and N. Kerlero de Rosbo J. Neurology 243, Suppl. 1, S14-S22 (1996).
  168. Cop 1 as a candidate drug for multiple sclerosis. D. Teitelbaum, R. Arnon and M. Sela, J. Neural Transmission, Volumes 3 and 4, Suppl. 49, p. 85 (1997).
  169. Christian Boehmer Anfinsen M. Sela, Proc. Amer. Philosoph. Soc. 140, 557 (1996).
  170. Ephraim Katchalski-Katzir at 80. M. Sela and N. Sharon, Protein Science 5, 801 (1996).
  171. Copolymer 1: from basic research to clinical application. D. Teitelbaum, R. Arnon and M. Sela, Cellular and Molecular Life Sciences 53, 24 (1997)
  172. Different roles of D-amino acids in immune phenomena M. Sela and E. Zisman, FASEB J. 11, 449 (1997).
  173. The crucial role of immunology as a science and as a tool at the turn of the millenium. M. Sela, in "Reflection on Science at the Dawn of the Third Millenium", Commentarii, Vol. IV, No. 4, p. 139 (1997), Vatican City.
  174. Probing into the realm of proteins and immunity. M. Sela, Protein Science, 7, 1653 (1998).
  175. Cop 1 from the laboratory to FDA. D. Teitelbaum, M. Sela and R. Arnon, Israel J. Med. Sci. 33, 280 (1997).
  176. The concept of specific immune treatment against autoimmune diseases. M. Sela, Intern. Rev. Immunol. 18, 201 (1999).
  177. Development of copolymer 1 (Copaxone) as a specific drug against multiple sclerosis. D. Teitelbaum, R. Aharoni, M. Fridkis-Hareli, R. Arnon and M. Sela, in "The Decade of Autoimmunity," Y. Shoenfeld, ed. p. 191 (1999), Elsevier Science, publ.
  178. The involvement of myasthenogenic T cell epitopes and their analogs in the clinical manifestations and treatment of myasthenia gravis. E. Mozes and M. Sela, in "The Decade of Autoimmunity," Y. Shoenfeld, ed., p. 245 (1999), Elsevier Science, publ.
  179. Poly-a-amino acids - from a better understanding of immune phenomena to a drug a against multiple sclerosis. M. Sela, Acta Polymerica 49, 523 (1998).
  180. AFIRST, 14 ans de cooperation. M. Sela, Daguesh No. 33, p. 1 (1998).
  181. In praise of Irun Cohen. M. Sela
  182. AFIRST, quatorze ans de cooperation. M. Sela, La Jaune et la Rouge, No. 537, p. 49, 1998.
  183. Structural components responsible for peptide antigenicity. M. Sela, Applied Biochemistry and Biotechnology, 83, 63 (2000).
  184. Empty now.
  185. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. L.N. Klapper, M.H. Kirschbaum, M. Sela and Y. Yarden, Adv. Cancer Research (Eds. G.F. Van de Wonde and G. Klein) 77, 25 (2000).
  186. The concept of specificity in peptide vaccines for infectious, autoimmune and neoplastic diseases. M. Sela and R. Arnon, in "Science at the Turn of the Millenium," ed. E. Keinan,
  187. Specific vaccines against autoimmune diseases. M. Sela, Compt. rend. Acad. Sci., Serie III, 322, 933 (1999).
  188. Help for the aged and the disabled- the case of multiple sclerosis. The Carta of Human Duties M. Sela, Proc. Intl. Forum, June 20, 1998, San Vito al Tagliamento, Italy, p. 143 (1999).
  189. Assistenza per gli anziani e i disabili - il caso della sclerosi multiple. M. Sela, La Carta dei Doveri Umani, Proc. Intl. Forum, June 20, 1998. San Vito al Tagliamento, Italia, p. 33 (1999).
  190. The chemistry of the Copaxone Drug. R. Arnon and M. Sela, Chemicals in Israel, I, 16 (1999).
  191. The concept of specificity in treating autoimmune diseases. M. Sela, Intl. J. Immunorehabilitation, 2, 12 (2000).
  192. Cancer immunotherapy directed at growth factor receptors: the ErbB/HER network as a prototype. M. Sela, B. Schechter and Y. Yarden, in "Targeted therapy for cancer", K.N. Syrigos and K.J. Harrington, eds.
  193. Glatiramer acetate (copolymer 1) in the treatment of multiple sclerosis. M. Sela and D. Teitelbaum, Expert Opinion on Pharmacotherapy.

 Abstracts, Book Reviews, Etc.

  1. Synthesis of new water-soluble poly-a-amino acids: polycysteine, poly-tyrosine and poly-p-aminophenylalanine. E. Katchalski, A. Berger and M. Sela, Abstr. 2nd Internat. Congr. Biochem. (Paris), p. 105 (1952).
  2. Polytyrosine. E. Katchalski and M. Sela, Bull. Research Counc. Israel 2, 315 (1952).
  3. The terminal groups of polypeptides prepared from N-carboxy-a-amino acid anhydrides M. Sela and A. Berger, B. Res. Counc. Israel 4, 110 (1954).
  4. Branched polyamino acids. M. Sela and E. Katchalski, Experientia 11, 62 (1955).
  5. The molecular weight distribution of multichain polyamino acids and their possible use as blood volume expanders. E. Katchalski, M. Sela and M. Gehatia, B. Res. Counc. Israel 5A, 93 (1955).
  6. Synthesis and properties of multichain polyamino acids., M. Sela and E. Katchalski, Congress Handbook, 14th Internat. Congr. Chem. (Zurich), p. 156 (1955).
  7. A spectrometric study of copolymers of amino acids containing tyrosine. M. Sela and E. Katchalski, Abstr. 3rd Internat. Congr. Biochem. (Bruxelles), p. 9 (1955).
  8. Appearance of serine upon alkaline incubation of iodinated polytyrosine. M. Sela and S. Sarid, Abstr. 130th Am. Chem. Soc. Meeting (Atlantic City), p. 20C (1956).
  9. The ultraviolet absorption and optical rotation of some modified ribonucleases. M. Sela and C.B. Anfinsen, Abstr. 131st Am. Chem. Soc. Meeting (Miami), p. 54C (1957).
  10. Optical rotatory studies on proline-containing polymers. W.F. Harrington and M. Sela, Abstr. 133rd Am. Chem. Soc. Meeting (San Francisco), p. 33Q (1958).
  11. a-g Shifts and optical rotation of penicillinase. N. Citri, N. Garber and M. Sela, B. Res. Counc. Israel 9A, 104 (1960).
  12. A synthetic polypeptide with the properties of a specific antigen. M. Sela and R. Arnon, B. Res. Counc. Israel 9A, 111 (1960).
  13. Isolation of antibodies from antigen-antibody complex by selective proteolysis of the antigen. R. Arnon and M. Sela, B. Res. Counc. Israel 9Av, 112 (1960).
  14. The effect of urea and guanidine hydrochloride on the enzymatic activity and optical rotation of penicillinase. M. Sela, N. Citri and N. Garber, Abstr. 138th Am. Chem. Soc. Meeting (New York), p. 39C (1960).
  15. Factors determining the antigenicity of synthetic polypeptides. M. Sela, R. Arnon and S. Fuchs, Abstr. 5th Internat. Cong. Biochem. (Moscow), p. 423 (1961).
  16. Interactions governing the formation of the unique structure of ribonuclease from the reduced chain. E. Haber, M. Sela and C.B. Anfinsen, Fed. Proc. 20, 217 (1961).
  17. Water-soluble multichain polyamino acids N. Lupu, A. Yaron, M. Sela and A. Berger, B. Res. Counc. Israel 10A, 47 (1961).
  18. Tyrosine-glutamic acid copolymer, an inhibitor of ribonuclease through specific interaction. M. Sela, Internat. Cong. Biophys. (Stockholm), Abstr., p. 227 (1961).
  19. The reaction of partially alaninated ribonuclease with antibody. R.K. Brown, M. Sela, M.A. Trzpis and C.B. Anfinsen, N.Y. State Dept. Health, Ann. Rept. Div. Labs. Res. 1961, 63.
  20. Polyalanyl ribonuclease. M. Sela and C. B. Anfinsen, in M.A. Stahmann, Ed., "Polyamino Acids, Polypeptides and Proteins", University of Wisconsin Press, Wisconsin, p. 311 (1962).
  21. The role of the locus of the immunogenic site and of the molecular size and shape in the antigenicity of some synthetic polypeptides. S. Fuchs, R. Arnon and M. Sela, B. Res. Counc. Israel 11A, 58 (1962).
  22. Isolation on Sephadex of antibodies to a synthetic polypeptide antigen and to lysozyme. D. Givol, S. Fuchs and M. Sela, B. Res. Counc. Israel 11A, 60 (1962).
  23. Helix-coil transition of poly-(g-hydroxypropyl)-L-glutamine in water and organic solvents. A. Yaron, N. Lupu, A. Berger and M. Sela, B. Res. Counc. Israel 11A, 87 (1962).
  24. Enzymatic properties of polyalanyl ribonuclease. D. Wellner, H.I. Silman and M. Sela, Abstr. 143rd Am. Chem. Soc. Meeting, Cincinnati, January 1963, p. 33A.
  25. Synthetic polypeptide antigens and their antibodies. M. Sela, S. Fuchs and D. Givol, Abstr. 143rd Am. Chem. Soc. Meeting, Cincinnati, January 1963, p. 9A.
  26. Further studies on polypeptide antigens. S. Fuchs and M. Sela, Israel J. Chem. 1, 54 (1963).
  27. Peptides maps of antibody and g-globulin fragments. D. Givol and M. Sela, Israel J. Chem. 1, 55 (1963).
  28. Two species of rabbit g-globulin. E. Mozes, D. Givol and M. Sela, Israel J. Chem. 1, 58 (1963).
  29. Synthetic antigens. M. Sela, Symposium Papers, 6th Internat. Congr. Biochem., New York, 1964, p. 123.
  30. Synthetic polypeptides as model antigens. M. Sela, Abstr. Symposium Papers, Gesellschaft fur physiologische Chemie, Mosbach, 1964, p. 34.
  31. Current thoughts on the structural basis of antigens and antibodies. M. Sela, Israel J. Exp. Med. 11, 223 (1964).
  32. Immune response to oligotyrosine derivatives. F. Borek, Y. Stupp and M. Sela, Abstr. 6th European Congress of Allergology, Stockholm, September 1965, p. 54.
  33. Chemical characterization of viperotoxin. C. Moroz, A. de Vries and M. Sela, Israel J. Chem. 3, 108 (1965).
  34. Reoxidation of fully reduced polyalanyl rabbit immunoglobulin G. M.H. Freedman and M. Sela, Israel J. Chem. 3, 123 (1965).
  35. Correlation between the net electrical charge of antigens and that of antibodies elicited by them. E. Mozes and M. Sela, Israel J. Chem. 3, 115 (1965).
  36. Poly-DL-alanyl myosin: A novel form of myosin soluble in dilute salt solutions. I.S. Edelman, E. Stier, S. Bauminger and M. Sela, Abstr. 303, 2nd Internat. Congr. Biophys., Vienna, September 1966.
  37. Polylysyl ribonuclease. A. Frensdorff and M. Sela, Israel J. Chem. 4, 85p (1966).
  38. Chemical modification of phages and their use in immunological studies. J. Haimovich and M. Sela, Abstr. Bacteriophage Meetings, Cold Spring Harbor and Naples, p. 80 (1966).
  39. Genetic control of the antibody response. H.O. McDevitt and M. Sela, Abstr. Meet. Amer. Rheumatism Soc., Arthritis and Rheumatism 9, 866 (1966).
  40. Neurotoxic protein in Vipera palestinae venom. C. Moroz, A. de Vries and M. Sela, Animal Toxins, p. 303, Pergamon Press, 1967.
  41. Empty for now.
  42. Antibodies specific to a natural glycolipid obtained with a synthetic polypeptide conjugate. M. Sela, R. Arnon, D. Shapiro and E.S. Rachaman, Abstr. Symp. on Contributions to the Pathogenesis and Etiology of Demyelinating Diseases, Locarno, May-June 1967, p. 40.
  43. Role of conformation in antigenicity and in antibody specificity. M. Sela, Abstr. Symposium Papers, 7th Internat. Cong. Biochem., Tokyo, 1967, Vol. I, p. 31.
  44. Synthetic polypeptide antigens derived from multichain polyproline. J.-C. Jaton and M. Sela, Israel J. Chem. 5, 104p (1967).
  45. Antibody combining sites to defined peptide determinants of increasing size. B. Schechter, I. Schechter and M. Sela, Israel J. Chem. 6, 107p (1968).
  46. Inactivation of phage and modified phage by antibodies of IgG and IgM class. J. Haimovich and M. Sela, Israel J. Chem. 6, 106p (1968).
  47. Antigens and Antigenitat. M. Sela, Mitteilungen der Gesellschaft Deutscher Naturforscher and Arzte, Nr. 2, p. 5, 1968.
  48. The relationship of antibody response to histocompatibility antigens. H.O. McDevitt and M. Sela, Abstr. Meet. Amer. Rheumatism Soc., Arthritis and Rheumatism 11, 107 (1968).
  49. Reaction of antibodies against sequential and conformational determinants with chemically related peptides. B. Schechter, I. Schechter, M. Sela and E. Benjamini, Israel J. Med. Sci. 5, 436 (1969).
  50. Specific fractionation of antibodies against a defined peptide determinant. B. Schechter, I. Schechter and M. Sela, Israel J. Med. Sci. 5, 436 (1969).
  51. Inhibition of the inactivation of modified phage. J. Haimovich, N. Novik and M. Sela, Israel J. Med. Sci. 5, 438 (1969).
  52. Effect of dioxane on the reaction of an uncharged antigen with its antibody. E. Hurwitz, J. Haimovich and M. Sela, Israel J. Med. Sci. 5, 437 (1969).
  53. The nature of the antigenic determinant in the genetic control of the antibody response. E. Mozes, H.O. McDevitt and M. Sela, Fed. Proc. 28, 570 (1969).
  54. Immunology as a model for biological organization. M. Sela, Abstr. Symposium on "Molecular Aspects of Biological Organization", Mexico, December 1969, p. 5.
  55. Immunology and nucleic acids (Book Review). M. Sela, Nature 224, 989 (1969).
  56. Detection of proteins with chemically modified bacteriophages. M. Sela and J. Haimovich, Abstr. 18th Ann. Colloquium, Protides of Biological Fluids, p. 93, April-May 1970.
  57. On the combining sites of antibodies to defined determinants. M. Sela, Abstr. The Second Annual Biochemistry - PCRI Winter Symposia, January 1970, Miami, Florida, No. 24.
  58. Detection of antibodies against proteins and of protein antigens by the use of protein bacteriophage conjugates. J. Haimovich, E. Hurwitz, N. Novik and M. Sela, Israel J. Med. Sci. 6, 449 (1970).
  59. Detection of cells reacting specifically with antigenic determinants by means of chemically modified bacteriophages. A. Sulica, J. Haimovich and M. Sela, Israel J. Med. Sci. 6, 450 (1970).
  60. Anti-inosine antibodies. H. Inouye, S. Fuchs and M. Sela, Israel J. Med. Sci. 6, 442 (1970).
  61. Spingomyelin-specific antibodies elicited by synthetic conjugates. D. Teitelbaum, R. Arnon, M. Sela, Y. Rabinsohn and D. Shapiro, Israel J. Med. Sci. 6, 442 (1970).
  62. Differences in frequency of anti-(T,G)-Pro--L splenic precursor cells in high responder and low responder inbred mouse strains. G.M. Shearer, E. Mozes and M. Sela, Israel J. Med. Sci. 6, 457 (1970).
  63. Cross-reaction of antibodies against random and ordered copolymers of the same amino acid composition. A. Conway-Jacobs, B. Schechter and M. Sela, Israel J. Med. Sci. 6, 440 (1970).
  64. Further studies on a unique antigenic region in lysozyme. E. Maron, C. Shiozawa, R. Arnon and M. Sela, Israel J. Med. Sci. 6, 443 (1970).
  65. Reduction of the immunological manifestations of penicillins. S. Shaltiel, R. Mizrahi, Y. Stupp and M. Sela, Israel J. Med. Sci. 6, 444 (1970).
  66. Solubilization of lymphocyte antigens by chemical means. Z. Eshhar, M. Gafni, D. Givol and M. Sela, Israel J. Med. Sci. 6, 448 (1970).
  67. Cellular basis of genetic control of immunity to synthetic polypeptides based on multichain polyproline. G.M. Shearer, E. Mozes and M. Sela, Immunochemistry 7, 872 (1970).
  68. Penicillin IgE antibodies in newborns and mothers detected by chemically modified bacteriophages. S. Levin, Y. Altman and M. Sela, Israel J. Med. Sci. 6, 742 (1970).
  69. On antibody formation to defined determinants. M. Sela, Proc. 8th Symp. Collegium Internationale Allergologicum (Montreux), Internat. Arch. Allergy Appl. Immunol. 41, 180 (1971).
  70. Further cellular studies on the correlation between the net electrical charge of immunogens and of the antibodies produced. Y. Karniely, G.M. Shearer, E. Mozes and M. Sela, Israel J. Med. Sci. 7, 625 (1971).
  71. Conformational changes induced in a periodic polymer by specific antibodies. B. Schechter, A. Conway-Jacobs and M. Sela, Israel J. Med. Sci. 7, 624 (1971).
  72. Enhancement of genetically controlled low immune responses to synthetic polypeptides by administration of polynucleotides, methylated albumin or peritoneal cells. E. Mozes, G.M. Shearer and M. Sela, Israel J. Med. Sci. 7, 611 (1971).
  73. Role of marrow cells and lack of role of thymocytes in the genetic control of immune responses to (Phe,G)-Pro--L. G.M. Shearer, E. Mozes and M. Sela, Israel J. Med. Sci. 7, 612 (1971).
  74. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. D. Teitelbaum, A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela, Israel J. Med. Sci. 7, 630 (1971).
  75. Excitation energy transfer from antibodies to dansylated antigen. Studies with the "loop" peptide of lysozymes. I. Pecht, E. Maron, R. Arnon and M. Sela, Israel J. Med. Sci. 7, 616 (1971).
  76. A general method for the preparation of nucleoside-bacteriophage T4 conjugates. B. Bonavida, S. Fuchs and M. Sela, Israel J. Med. Sci. 7, 635 (1971).
  77. Immunologic unresponsiveness to synthetic antigens derived from multi-chain polyproline in adult mice and circumvention of tolerance following immunization with cross-reacting antigens. B. Bonavida, E. Mozes, G.M. Shearer and M. Sela, Israel J. Med. Sci. 7, 613 (1971).
  78. Dynamics of binding of DNP ligands to a myeloma protein. I. Pecht, D. Givol and M. Sela, Israel J. Med. Sci. 7, 615 (1971).
  79. The stimulation of anti-hapten antibodies with protein carrier. R. Tarrab, P. Strausbauch, A. Sulica and M. Sela, Israel J. Med. Sci. 7, 619 (1971).
  80. Use of Sepharose-bound anti-dinitrophenyl antibodies for the isolation of a specific tRNA substituted selectively with dinitrophenyl groups. S. Fuchs, B. Bonavida, M. Sela, E. Ziv, S. Rappoport and Y. Lapidot, Israel J. Med. Sci. 7, 636 (1971).
  81. Determinant-specific genetic control of immune response. M. Sela, E. Mozes and G.M. Shearer, Abstr. Commun. 7th Meet. Eur. Biochem. Soc. (Varna), 1971, p. 83.
  82. A synthetic polypeptide for suppression of experimental allergic encephalomyelitis. R. Arnon, D. Teitelbaum, A. Meshorer, T. Hirshfeld and M. Sela, Abstr. Commun. 7th Meet. Eur. Biochem. Soc. (Varna), 1971, p. 287.
  83. Kinetic mapping. II. The characterization of the binding site of a myeloma protein with anti-2,4-dinitrophenyl activity. D. Haselkorn, I. Pecht, S. Friedman, A. Yaron, D. Givol and M. Sela, Abstr. 41st Ann. Meet. Israel Chem. Soc. 17-21 Oct., 1971, p. 53.
  84. A synthetic polypeptide as an immunological model for collagen. A. Maoz, S. Fuchs and M. Sela, Abstr. 14th Ann. Meet. Israel Chem. Soc. 17-21 Oct., 1971, p. 51.
  85. Reactia anticorpilor cu lizozim nativ provocata de un antigen complet sintetic. Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. R. Arnon, E. Maron, M. Sela and C.B. Anfinsen, Abstr. First Romanian Symposium of Immunology, Bucharest, September 1971, pp. 3, 99.
  86. Structura antigenului si biosinteza anticorpilor. Antigen structure and antibody biosynthesis. M. Sela, Abstr. First Romanian Symposium of Immunology, Bucharest, Sept. 1971, pp. 66, 164.
  87. Controlul genetic al raspunsului imun, in corelatie cu numarul celulelor peritoneale. Genetic control of immune response correlated with the number of peritoneal cells. A. Sulica, E. Mozes, G.M. Shearer and M. Sela, Abstr. First Romanian Symposium of Immunology, Bucharest, Sept. 1971, pp. 82, 180.
  88. Penicillin and dinitrophenyl antibodies in newborns and mothers detected with chemically modified bacteriophage. S. Levin, Y. Altman and M. Sela, Pediatric Research 5, 87 (1971).
  89. Immune response to collagen provoked by the synthetic polypeptide (L-Pro-Gly-L-Pro)n. A. Maoz, S. Fuchs and M. Sela, Israel J. Med. Sci. 8, 657 (1972).
  90. Use of cell fractionation on polylysine-coated glass beads in studies of the inverse relationship between the net charge of antigens and antibodies. Y. Karniely, E. Mozes, G.M. Shearer and M. Sela, Israel J. Med. Sci. 8, 642 (1972).
  91. Are slowly-metabolized immunogens thymus-independent? E. Mozes, G.M. Shearer and M. Sela, Israel J. Med. Sci. 8, 647 (1972).
  92. Genetic control of the immune response to (H,G)-Pro--L. E. Mozes, S. Shaltiel and M. Sela, Israel J. Med. Sci. 8, 650 (1972).
  93. Differences in the contribution of thymocytes to the genetic regulation of immune responses as a function of the polymeric side chains of synthetic immunogens. G.M. Shearer, E. Mozes and M. Sela, Israel J. Med. Sci. 8, 649 (1972).
  94. Differences in the contribution of thymocytes to the genetic regulation of immune responses to (T,G)-A--L as a function of the inbred mouse strain. L. Lichtenberg, G.M. Shearer, E. Mozes and M. Sela, Israel J. Med. Sci. 8, 649 (1972).
  95. The mechanism of antigenic competition. M.J. Taussig, E. Mozes, G.M. Shearer and M. Sela, Israel J. Med. Sci. 8, 661 (1972).
  96. Non-specific antigenic stimulation. M. Bustin, P.H. Strausbauch, R. Tarrab, A. Sulica and M. Sela, Israel J. Med. Sci. 8, 660 (1972).
  97. Immunological implications of extracellular receptors for histamine on human leukocytes and mouse spleen cells. K.L. Melmon, Y. Weinstein, G.M. Shearer, H.R. Bourne and M. Sela, Israel J. Med. Sci. 8, 641 (1972).
  98. Biochemical and immunological properties of the chemically solubilized antigens from rat thymocytes. Z. Eshhar, T. Waks, M. Bustin and M. Sela, Israel J. Med. Sci. 8, 643 (1972).
  99. Further studies on the suppression of EAE by a synthetic copolymer. C. Webb, D. Teitelbaum, A. Meshorer, R. Arnon and M. Sela, Israel J. Med. Sci. 8, 656 (1972).
  100. Binding parameters of antibodies specific toward a unique antigenic region of lysozyme. E. Maron, R. Arnon and M. Sela, Israel J. Med. Sci. 8, 635 (1972).
  101. Use of 1,5-difluoro-2,4-dinitrobenzene for coating of bacteriophages with proteins and polymers. R. Mizrahi, S. Shaltiel and M. Sela, Israel J. Med. Sci. 8, 658 (1972).
  102. Anti-inosine antibodies and their potential use in tRNA studies. H. Inouye, S. Fuchs, M. Sela and U.Z. Littauer, Abstr. 8th Meet. Fed. Eur. Biochem. Soc. (Amsterdam), 1972, abstr. 797.
  103. Structural features of antigens. M. Sela, Abstr. 8th Meet. Fed. Eur. Bioch. Soc. (Amsterdam), 1972, abstr. 676.
  104. Empty for now
  105. Histamine receptors and immunologic function of leukocytes. K.L. Melmon, G.M. Shearer, Y. Weinstein and M. Sela, J. Clin. Invest. 51, 65a (1972).
  106. Genetic control and immunity. E. Mozes, G.M. Shearer and M. Sela, Israel J. Med. Sci. 8, 1001 (1972).
  107. Suppression of experimental allergic encephalomyelitis by a synthetic copolymer immunologically cross-reactive with basic encephalitogen. R. Arnon, D. Teitelbaum, C. Webb, A. Meshorer and M. Sela, Israel J. Med. Sci. 8, 1759 (1972).
  108. Histopathology of experimental allergic encephalomyelitis in guinea pigs. A. Meshorer, D. Teitelbaum, C. Webb, R. Arnon and M. Sela, Israel J. Med. Sci. 8, 1760 (1972).
  109. Antigen design and its role in antibody synthesis. M. Sela, S. Fuchs, A. Maoz, E. Mozes and M. Becker, Abstr. 9th Internat. Congr. Biochem., Stockholm, July 1973, p. 302.
  110. Antigen design, cell recognition and immune response. M. Sela Abstr. Simposio Cientifico Mexicano Israeli, Biology, p. 1 (1973).
  111. The role of the thymus in the immune response to collagen-like polypeptides. S. Fuchs, E. Mozes, A. Maoz and M. Sela, Abstr. Joint Meeting Immunol. (Strasbourg), p. 25 (1973).
  112. Cytotoxic activity of antibodies to a collagen-like polymer on cells in culture. A. Maoz, H. Dym, S. Fuchs and M. Sela, Abstr. Joint Meeting Immunol. (Strasbourg), p. 50 (1973).
  113. Synthetic conjugates capable of eliciting sphingomyelin specific antibodies. D. Teitelbaum, R. Arnon and M. Sela, Abstr. Joint Meeting Immunology (Strasbourg), p. 77 (1973).
  114. Synthetic copolymers immunologically cross-reactive with basic encephalitogen. C. Webb, D. Teitelbaum, R. Arnon and M. Sela, Abstr. Joint Meeting Immunology (Strasbourg), p. 85 (1973).
  115. Magnitude and class of antibodies produced in inbred mnouse strains toward a thymus independent synthetic polypeptide. A.-M. Schmitt, E. Mozes and M. Sela, Abstr. Joint Meeting Immunology (Strasbourg), p. 70 (1973).
  116. The role of the thymus in a genetically controlled defect at the carrier level. M. Sela and E. Mozes, Abstr. Joint Meeting Immunology (Strasbourg), p. 73 (1973).
  117. The cellular basis of the enhancing effect of syngeneic peritoneal macrophages in low responders to poly(Tyr,Glu)-polyPro-polyLys. F. Falkenberg, E. Mozes, G.M. Shearer, A. Sulica and M. Sela, Abstr. Joint Meeting Immunology (Strasbourg), p. 22 (1973).
  118. Antigenicity of p-azobenzenearsonate (ABA)-L-tyrosine-containing oligopeptides in rabbits. M.J. Becker, H. Levin and M. Sela, Abst. Joint Meeting Immunol. (Strasbourg) p. 4 (1973)
  119. Strain-dependent differences in the response towards penicillin. R. Mizrahi, S. Shaltiel, G.M. Shearer, E. Mozes and M. Sela, Abstr. Joint Meeting Immunology (Strasbourg), p. 53 (1973).
  120. Shape and volume of anti-poly-D-alanyl antibodies in the presence and absence of tetra-D-alanine as followed by small angle x-ray scattering. I. Pilz, O. Kratky, A. Licht and M. Sela, Appl. Crystallography 7, 187 (1974).
  121. Specific antibodies to yeast phenylalanine transfer ribonucleic acid. A. Aharonov, S. Fuchs and M. Sela, Israel J. Med. Sci. 10, 1172 (1974).
  122. Fractionation of lymphocytes sensitized to basic encephalitogen. C. Webb, D. Teitelbaum, Y. Karniely, R. Arnon and M. Sela, Israel J. Med. Sci. 10, 1177 (1974).
  123. Dose response studies on experimental allergic encephalomyelitis suppression by Cop 1. D. Teitelbaum, C. Webb, R. Arnon and M. Sela, Israel J. Med. Sci. 10, 1172 (1974).
  124. The ordered tetrapeptide Tyr-Tyr-Glu-Glu representing a major determinant of the random polypeptide poly(Tyr,Glu)-polyDLAla--polyLys. M. Schwartz, E. Mozes and M. Sela, Israel J. Med. Sci. 10, 1173 (1974).
  125. Ir-controlled cell-mediated immune responses in vivo to synthetic polypeptides and a protein. S. Davis, G.M. Shearer, D.H. Sachs, E. Mozes and M. Sela, Abstr. Ninth Leukocyte Culture Conference, December 1974, Williamsburg, Virginia, p. 53.
  126. Specific cytotoxicity of drugs chemically linked to antibody. R. Levy, E. Hurwitz, R. Maron, R. Arnon and M. Sela, Abstr. Fifth Internat. Cong. Transplantation Soc., August 1974, Jerusalem, Israel, p. 70.
  127. Specific cytotoxicity of drugs chemically linked to antibody. R. Levy, E. Hurwitz, R. Maron, R. Aron and M. Sela, Abstr. XIth Internat. Cancer Congr., October 1974, Florence, Italy, p. 750.
  128. Synthetic approaches to some applied aspects of antigenicity. M. Sela, Abstr. Seventh Annual Miami Winter Symposia, p. 52, 1975.
  129. The immune response potential of inbred mouse strains to two ordered peptides of tyrosine and glutamic acid as compared with their response to random (T,G)-A--L. M. Schwartz, E. Mozes and M. Sela, Israel J. Med. Sci. 11, 1376 (1975).
  130. Lack of inverse relationship between the net charge of thymus independent immunogens and the responding spleen cells. F. Falkenberg, Y. Karniely, E. Mozes and M. Sela, Israel J. Med. Sci. 11, 1377 (1975).
  131. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. C. Webb, D. Teitelbaum, O. Abramsky, R. Arnon and M. Sela, Israel J. Med. Sci. 11, 1388 (1975).
  132. Strain differences in the immune response to the encephalitogenic determinant in inbred guinea pigs. D. Teitelbaum, C. Webb, R. Arnon and M. Sela, Israel J. Med. Sci. 11, 1389 (1975).
  133. Immunological cross-reaction of antibodies to a synthetic undecapeptide of carcinoembryonic antigen with the intact protein and with human sera. R. Arnon, M. Bustin, E. Calef, S. Chaichik, J. Haimovich, N. Novik and M. Sela, Israel J. Med. Sci. 11, 1399 (1975).
  134. Genetic control of the immune response to ordered peptides of tyrosine and glutamic acid. M. Schwartz, E. Mozes and M. Sela, Abstr. Fifth International Conference on Lymphatic Tissue and Germinal Centers in Immune Reaction, Tiberias, June 1975, in M. Feldman and A. Globerson, eds., "Immune Reactivity of Lymphocytes", Plenum Press, 1976, p. 545.
  135. Antigen pattern, immunity and genetic control of immune response. M. Sela and M. Schwartz, Abstr. 10th Internat. Congr. Biochem., Hamburg, July 1976, p. 464.
  136. The use of antibodies to tumor cells as carriers of chemotherapeutic agents in murine experimental tumor systems. H. Hurwitz, R. Maron, R. Arnon and M. Sela, Fed. Proc. 35, 826 (1976).
  137. Pure isoallergens from Timothy Grass pollen. N. Smorodinsky, R. Cesla, C. Geller-Bernstein, S. Shaltiel and M. Sela, Israel J. Med. Sci. 12, 1246 (1976).
  138. Antigenic determinants in the random synthetic polypeptide (Phe,G)-A--L. R.J. Hooghe, R.I. Zemell, M. Schwartz, E. Mozes and M. Sela, Israel J. Med. Sci. 12, 1236 (1976).
  139. Comparison between the affinity values of high and low responders' antibodies specific to the ordered polypeptide (Tyr-Tyr-Glu-Glu)-A--L. M. Schwartz, E. Mozes and M. Sela, Israel J. Med. Sci. 12, 1236 (1976).
  140. The role of antigenic structure in cell to cell cooperation and genetic control of immune response. M. Schwartz, R.J. Hooghe, E. Mozes and M. Sela, Abstr. 3rd European Immunology Meet., p. 126, Copenhagen 1976, Scand. J. Immunol. 6, 747 (1977).
  141. The nature of the genetic defect in low responder (H-2)k mice to (T,G)-A--L. M. Schwartz, E. Mozes and M. Sela, Abstr. 3rd European Immunology Meet., p. 126, Copenhagen 1976, Scand. J. Immunol. 6, 747 (1977).
  142. Structure de l'antigene et controle de la reponse immunitaire. M. Sela, Abstr. Congres Francophone International d'Immunologie, Pointe au Pic, Quebec, Canada, October 1976, p. 8.
  143. Tolerance induction confirms that (Tyr-Tyr-Glu-Glu)-poly(DLAla)--poly(Lys) is the major determinant of the random poly(Tyr,Glu)-poly(DLAla)--poly(Lys). M. Schwartz, E. Mozes and M. Sela, Israel J. Med. Sci. 13, 1054 (1977).
  144. The adjuvant effect of peptidoglycan in the immune response to a synthetic fragment of the MS-2 bacteriophage. H. Langbeheim, R. Arnon and M. Sela, Israel J. Med. Sci. 13, 1054 (1977).
  145. Use of antibodies for delivery of chemotherapeutic drugs. M. Sela, Abstr. (Vatican). 1977.
  146. Synthetic antigens in molecular, cellular and applied studies. M. Sela, Abstr. Internat. Symp. on Proteins, Academia Sinica, Taipei, Taiwan, p. 78 (1978).
  147. Mechanism of action of daunomycin-antibody conjugates. E. Hurwitz, R. Maron, R. Arnon, M. Wilchek and M. Sela, Israel J. Med. Sci. 15, 183 (1979).
  148. Antibodies against a primary tumor cell as specific drug-carriers to the metastatic tumor cell in vitro. E. Hurwitz, B. Schechter and M. Sela, Israel J. Med. Sci. 15, 183 (1979).
  149. The mode of interaction with macrophages of two ordered peptide antigens which differ in their thymus dependency. R. Hooghe, M. Schwartz, B. Geiger, M. Bar-Eli, R. Galily, E. Mozes and M. Sela, Abstr. Meeting Reticuloendothelial Society.
  150. Antiviral antibodies: combined use of synthetic antigens and synthetic adjuvants. M. Sela, E. Mozes and R. Arnon, J. Infectious Diseases.
  151. Anti-viral response elicited by a completely synthetic antigen with built-in adjuvanticity. R. Arnon, M. Sela and L. Chedid, Abstr. 4th Internat. Congr. Immunology (Paris), 17.8.02., 1980.
  152. Antiviral antibodies obtained with aqueous solution of a synthetic antigen. M. Sela, Oholo Biological Conferences, 1980, p. 39.
  153. Effect of anti-rat AFP specific antibody daunomycin conjugates on the growth of AFP-producing ascites hepatoma AH 66 cell line. Y. Tsukada, W.K.-D. Bischof, E. Hurwitz, M. Sela and H. Hirai, Abst. VIIIth Meeting Internat. Soc. Oncodevelopmental Biology and Medicine, Tallin (Estonia, USSR), "Embryonic Antigens in Cancer", September 1980, p. 22.
  154. The fine specificity of T-B cell collaboration in response to the ordered analogs of the random (T,G)-A--L. B. Parhami, E. Mozes and M. Sela, Israel J. Med. Sci. (p. 52 of Abst).
  155. Effect of a conjugate of daunomycin and purified polyclonal or monoclonal antibodies to rat a-fetoprotein on the growth of a-fetoprotein-producing tumour cells. Y. Tsukada, N. Hibi, A. Hara, E. Hurwitz, M. Sela and H. Hirai, Abst. 10th Meet., Internat. Soc. Oncodevelopmental Biology and Medicine, Sapporo (Japan), September 1982, A74.
  156. Synthetic antigens, adjuvants and carriers for synthetic vaccines. M. Sela, Abstr. EMBO Workshop on "Towards New Vaccines Against Virus Infections", June 1983, Helsinki.
  157. Synthetic approaches to vaccination against bacterial toxins. M. Sela, C.O. Jacob and R. Arnon, Abstr. Conference on "Modern Approaches to Vaccines", August 1983, Cold Spring Harbor, N.Y., p. 30.
  158. Synthetic antigens, adjuvants and vaccines. M. Sela, Abstr. 3rd Congress of the Federation of Asian and Oceanian Biochemists, November 1983, Bangkok.
  159. Heritability of IgA levels in atopic families. C. Geller-Bernstein, R. Kenett, S. Tsur, L. Weissglas, A. Bejerano, M. Lahav and M. Sela, Abstr. XII Cong. Eur. Acad. Allerg. Clin. Imm., Rome, Sept. 25-30, 1983, Folia Allergologica et Immunologica Clinica, 30, Suppl. 4, 105 (1983).
  160. Clinical trials of a synthetic polypeptide (Copolymer 1) for the treatment of multiple sclerosis. M.B. Bornstein, A.I. Miller, S. Slagle, V. Spada, R. Arnon, M. Sela and D. Teitelbaum, 25th Anniversary Symposium of the Belgian Research Group for Multiple Sclerosis, Brussels, April 1983, p.
  161. Towards totally synthetic vaccines. M. Sela, Abstr. 16th Meet. FEBS., Moscow, June 1984, p. 96.
  162. Molecular engineering of the immune system. M. Sela, Abstr. Internat. Symposium "Frontiers in Bioorganic Chemistry and Molecular Biology", Moscow - Alma-Ata (Kazakhstan), June 1984, p. 65.
  163. Low immunoglobulin A in atopic families. C. Geller-Bernstein, R. Kenett, N. Keret, A. Bejerano, S. Tsur, L. Weissglass, M. Lahav and M. Sela, Abst. 15 Meeting Israel Immunol. Soc., Tel Aviv, p. 70 (1984)
  164. Overview: retrospect and prospects for synthetic vaccines: peptides, adjuvants and conjugates. M. Sela, Sclavo International Conference on Synthetic Antigens, Sienna, Italy 29-30 Oct. 1984, p. 9.
  165. Synthetic vaccines: present and future. R. Arnon and M. Sela, Abstr. Symp. 100 Years from Rabies Vaccination. Pasteur Inst., Paris 1985.
  166. Multiple sclerosis: clinical trials of a synthetic polypeptide, Copolymer 1. M.B. Bornstein, A. Miller, S. Slagle, V. Spada, R. Arnon, D. Teitelbaum and M. Sela, 37th Meet. Amer. Acad. Neurology, Neurology, Supplement 1, 35, 103 (1985).
  167. Conjugation of adriamycin to monoclonal antibodies against a human hepatoma associated cell surface antigen. D. Shouval, J.R. Wands, R. Adler, M. Eliakim, M. Sela and E. Hurwitz, Abstr. Ann. Meeting American Association for the Study of Liver Diseases, Hepatology 5, 972 (1982).
  168. Multiple sclerosis clinical trials with a synthetic polypeptide, Cop. 1. R. Arnon, D. Teitelbaum, M. Sela and M. Bornstein, Abst. 7th European Immunology Meeting, Jerusalem, p. 64, 1985.
  169. Effect of a conjugate of adriamycin to monoclonal antibodies against HBsAg on growth of a human hepatoma cell line persistently infected with hepatitis B virus. D. Shouval, J.R. Wands, M. Eliakim, R. Adler, M. Sela and E. Hurwitz, Abstr. American Gastroenterological Association, Gastroenterology 88, 1585 (1985).
  170. Totally synthetic immunogen provoking protective anti-cholera antibodies when administered in aqueous solution. M. Sela, C.O. Jacob and R. Arnon, Abstr. VI Intl. Congress of Immunology, Toronto, p. 251 (1986).
  171. Priming immune response to cholera toxin induced by synthetic peptides. C.O. Jacob, S. Grossfeld, M. Sela and R. Arnon, Abst. VIth Intl. Congress of Immunology, Toronto, p. 252 (1986).
  172. Localization and treatment of hepatocellular carcinoma by monoclonal antibodies to hepatoma associated proteins. D. Shouval, J.R. Wands, R.Adler, E. Galun, M. Sela and E. Hurwitz, Abstr. International Symposium on the Immunology of the Gastrointestinal Tract and the Liver, p. L50, Jerusalem, Israel (1986).
  173. Homing of iodine-125 labelled antibodies directed against EGF receptor to human epidermoid carcinoma (KB) implanted in nude mice. E. Aboud-Pirak, E.Hurwitz, F. Bellot, J. Schlessinger and M. Sela, Abstr. 18 Meeting Israel Immunol. Soc., (1987).
  174. Cop 1 as an inhibitor of specific T cell response to BP. D. Teitelbaum, R. Aharoni, R. Arnon and M. Sela, Abst. Europ. Immunol. Meet., Roma, Sept. 1988, p.92.
  175. The "loop" epitope of hen egg white lysozyme - conformational, cellular and immunogenetical aspects. R. Arnon, M. Sela and I. Pecht, Abstr. Workshop on "Immunology of Lysozyme", June 1988, Bethesda, Md.
  176. Foreward to the book on "Multifunctional IgG and IgG-binding Receptors" by J. Gergely, Akademiai Kiado, Budapest, 1988.
  177. Synthetic macromolecular antigens, drugs and vaccines M. Sela, Proc. Symposium on "Synthetic and Genetic Engineering Vaccines", Instituto Butantan, Sao Paulo, p. (1988).
  178. Cop 1 in chronic-progressive multiple sclerosis. M. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, V. Spada, W. Weiss, S. Appel, L. Rolak, S. Brown, Y. Harati, R. Arnon, I. Jacobsohn, D. Teitelbaum and M. Sela. Abstr. Intl. Conf. on "An Update on Multiple Sclerosis", Rome, Sept. 1988, p.
  179. Conjugates of antibodies with cytotoxic drugs against experimental human solid tumors. E. Hurwitz and M. Sela, Abstr. Table Ronde Roussel-Uclaf No. 65, "Immunotargeting for Diagnosis and Therapy", p. 27, December 1989.
  180. A conjugate of 5-fluorouridine-poly-(L-lysine) and an antibody reactive with human colon carcinoma. I. Stancovski, E. Hurwitz, M. Sela, M. Wilchek, D. Shouval and J.R. Wands, Abstr. 20th Meeting Israel Immunol. Soc., Israel J. Med. Sci.
  181. Fluorouridine- and daunomycin-antibody conjugates against a human colon tumor in comparison to other tumor systems. E. Hurwitz and M. Sela, 20th Meeting FEBS, Budapest, August 1990.
  182. An immunomodulating vaccine against multiple sclerosis. M. Sela, Absts. First Israel-Soviet Seminar on Peptides and Proteins, Rehovot, p. 22, December 1991.
  183. CIDNP studies of immunogenic diversity in synthetic antigenic peptides. K.A. Muszkat, M. Sela and B. Schechter, 20th Annual Meeting, Keystone Symposia on Moleculer and Cellular Biology, J. Cellular Biochem., Suppl. 15G, p. 89, 1991.
  184. Inhibition of myelin basic protein specific human T cell lines by Cop 1. R. Milo, M. Sela, R. Arnon and D. Teitelbaum, 21st Ann. Meet. Israel Immunol. Soc., Israel J. Med. Sci. 28, 486 (1992).
  185. Crucial steps for MHC recognition leading to T cell stimulation by a random multichain polypeptide antigen. E. Zisman, M. Sela and E. Mozes, 21st Ann. Meet. Israel Imm. Soc. Abstr. p.18 (1991).
  186. Peptidic T-cell epitopes in acetylcholine receptor and in synthetic antigens. E. Mozes, E. Zisman, S. Kirshner, Y. Katz-Levy and M. Sela, Abstr. 15th Intl. Congress Biochem. (Jerusalem), p. 120, August 1991.
  187. Specific inhibition by the synthetic copolymer Cop 1 of human T cell lines specific to myelin basic protein. R. Teitelbaum, R. Milo, R. Arnon and M. Sela, Abstr. 3rd Intl. Conf. Neuroimmunology (Jerusalem), J. Neuroimmunol., Suppl. No. 1, p. 72 (1991).
  188. CIDNP studies of immunogenic diversity in synthetic antigenic peptides. K.A. Muszkat, M. Sela and B. Schechter, Abst. 15th Congress Biochem. (Jerusalem), p. 365, August 1991.
  189. Tumor-inhibitory antibodies to HER2/Neu receptor: biological and biochemical characterization. I. Stancovski, E. Hurwitz,S.S. Bacus, Y. Yarden and M. Sela, Israel J. Med. Sci.
  190. T cell epitopes of the human acetylcholine receptor related to myasthenia gravis. E. Zisman, S. Kirschner, Y. Katz-Levy, M. Sela and E. Mozes, Abstr. 8th Intl. Congr. Immunol., Budapest, August, 1992, W-100, 47, p. 628.
  191. T cell epitopes of synthetic polypeptide antigens M. Sela, E. Zisman and E. Mozes, Abstr. Symp. on T Cell Repertoire Sept. 1992, Arad, Israel, p. L-14.
  192. MHC-antigen-T cell interactions for thymus-dependent and thymus-independent antigens. E. Zisman, M. Sela and E. Mozes, Abstr. Symp. on T Cell Repertoire, Sept. 1992, Arad, Israel, p. P-33.
  193. T cell epitopes of the human acetylcholine receptor related to myasthenia gravis. S. Kirshner, E. Zisman, Y. Katz-Levy, M. Sela and E. Mozes, Abstr. Symp. on T Cell Repertoire, Sept. 1992, Arad, Israel,p. P-17.
  194. Direct binding of synthetic copolymer 1 to class II major histocompatibility complex molecules on antigen-presenting cells: affinity and specificity of the binding. M. Fridkis-Hareli, D. Teitelbaum, R. Arnon and M. Sela, Abstr. Meet. Israel Immunol. Soc., June 1993.
  195. T cell epitopes of synthetic antigens and of antigens related to autoimmune diseases. M. Sela, Abstr. XIIth Intl. Congr. Nephrology, Jerusalem, June 1993, p. 126.
  196. Study of the MHC-competition between BP and Cop 1 using human cytotoxic T-cell clones. E. Gurevich, D. Teitelbaum, M. Sela and R. Arnon, "Neuroimmunologia na Poroge XXI Veka" (Neuroimmunology at the porch of XXIth century), St. Petersburg, p. 179 (1993).
  197. Peripatetic view of immunotargeting in malignancy. M. Sela, Abstr. XXIst Meet. Intl. Soc. Oncodevelopmental Biol. and Med., Jerusalem, November 1993, p.
  198. Fighting cancer with monoclonals and autoimmune diseases with T cell epitopes. M. Sela, New Delhi, Jan. 1994.
  199. Immunological parameters in a multicenter clinical trial of Cop 1 in multiple sclerosis -- a 2-year follow up. D. Teitelbaum, Z. Meiner, T. Brenner, O. Abramsky, E. Kott, D. Schechter, B. Gutman, P. Nisipeanu, A.D. Korczun, K. Klein, S. Flechter, R. Arnon and M. Sela, Amer. Acad. Neurology.
  200. Microbial antigens linked to silica particles enhance intestinal mucosal immunity. R.S. Marks, D. Mirelman and M. Sela, Abstr. IUMS Congress, Prague, July 1994, p. 190.
  201. Synthetic copolymer 1 and myelin basic protein do not undergo processing prior to the binding to class II major histocompatibility complex molecules on antigen-presenting cells. M. Fridkis-Hareli, D. Teitelbaum, R. Arnon and M. Sela, Abst. Meet. Israel Immunol. Soc., May 1994, Israel J. Med. Sci.
  202. Specific and promiscuous binding of synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells. M. Fridkis-Hareli, D. Teitelbaum, E. Gurevich, I. Pecht, Ch. Brautbar, Oh Joong Kwon, T. Brenner, R. Arnon and M. Sela, Abstr. Meet. Israel Biochem. Soc., March 1994, Israel J. Med. Sci.
  203. Synthetic copolymer 1 inhibits the binding of MBP, PLP and MOG peptides to class II major histocompatibility complex molecules on antigen-presenting cells. M. Fridkis-Hareli, D. Teitelbaum, N. Kerlero de Rosbo, R. Arnon and M. Sela, Abst. 10th Meet. ESN (Eur. Soc. Neurochem.), August 1994, Jerusalem, J. Neurochem. 63, Suppl. 1, S61, 1994.
  204. Copolymer 1 - history and mechanism of action. M. Sela, Abstr. Multiple Sclerosis Medical Satellite Symp., Budapest, Sept. 1994, p. 53.
  205. Synthetic vaccines against autoimmune diseases. M. Sela, Abstr. Internat. Cooperation for Development of Biotechnology Conference, Jerusalem, Nov. 1994, p. 76.
  206. Specific inhibition of PLP reactive T cell lines and PLP-induced EAE by Copolymer 1. D. Teitelbaum, M. Fridkis-Hareli, R. Arnon and M. Sela, Abstr. 9th Intl. Congr. Immunol., San Francisco, July 1995, p. 846.
  207. T Cell epitopes of the human acetylcholine receptor a-subunit and their analogs as immunomodulators of myasthenia gravis. E. Zisman, S.L. Kirshner, Y. Katz-Levy, M. Dayan, O. Abramsky, H. Brautbar, M. Sela and E. Mozes, Abstr. 9th Intl. Cong. Immunol., San Francisco, July 1995, p. 844
  208. Copolymer 1 displaces MBP, PLP and MOG, but cannot be displaced by these antigens from the MHC class II binding site. M. Fridkis-Hareli, D. Teitelbaum, R. Arnon and M. Sela, Abstr. 9th Intl. Cong. Immunol., San Francisco, July 1995, p. 406.
  209. Vicinal side chain interaction in Tyr-Glu peptide antigens and its role in T cell recognition. K.A. Muszkat, M. Sela, V. Preygerzon, A. Jakob and L. Konstantinovskii, Abst. Meet. Israel Immunol. Soc., June 1995, Israel J. Med. Sci.
  210. Binding of synthetic copolymer 1 and myelin basic protein leads to increased expression of class II major histocompatibility complex molecules on antigen-presenting cells. M. Fridkis-Hareli, D. Teitelbaum, I. Pecht, R. Arnon and M. Sela, Abstr. Meet. Israel Immunol. Soc. June 1995, Israel J. Med. Sci.
  211. Vaccines and autoimmunity M. Sela, Abstr. Fourth Intl. Conf. on SLE, Jerusalem, March 1995, Lupus, 4 Suppl. A, p. 107.
  212. Antibodies to copolymer 1 do not interfere with its clinical effect. K.P. Johnson, the U.S. Phase III Copolymer 1 Study Group, D. Teitelbaum, R. Arnon and M. Sela, Meet. Amer. Neurological Assoc., Washington, Oct. 1995.
  213. A synthetic polymeric model of myelin basic protein serves as a candidate drug for multiple sclerosis. M. Sela, Abstr. 2nd Israeli-Polish Symposium on the Chemistry and Biology of Peptides and Proteins, p. 16, April 1995.
  214. Synthetic vaccines for infectious and autoimmune diseases. M. Sela, Abstr. 39th Oholo Conference on "Vaccines: Novel Strategies in Design and Production", Eilat, May 1995, p.1.
  215. Effect of Cop 1 on autoimmune T-cell reactivity to myelin- oligodendrocyte glycoprotein (MOG). A. Ben-Nun, I. Mendel, R. Bakimer, M. Fridkis-Hareli, D. Teitelbaum, R. Arnon, M. Sela and N. Kerlero de Rosbo, 1995.
  216. Copolymer 1 suppresses chronic-relapsing EAE induced in mice by PLP encephalitogenic peptides and interferes with the immune response to these peptides. D. Teitelbaum, M. Fridkis-Hareli, R. Arnon and M. Sela, Abst. 11th European Congress on Multiple Sclerosis (ECTRIMS), Jerusalem, Sept. 1995, J. Neuroimmunology, Suppl. 1, 1995, p. 19.
  217. Molecular studies of the therapeutic potential of monoclonal antibodies to the ErbB-2 receptor. L.N. Klapper, E. Hurwitz, Y. Yarden and M. Sela, Abstr. First Congress of FISEB (Federation of Israeli Societies of Experimental Biology), October 1995, Eilat, p. 65.
  218. Inhibition of allorecognition and prevention of graft-vs-host disease (GVHD) by GLAT, a synthetic polymer with promiscuous binding to murine and human MHC molecules. P.G. Schlegel, R. Aharoni, J. Chen, Y. Chen, D. Teitelbaum, R. Arnon, M. Sela and N. J. Chao, Abstr. Ann. Meet. Amer. Soc. Hematology.
  219. Immunotherapeutic approaches to autoimmune diseases and to cancer. M. Sela, Abstr. Intl. Conference on "New Frontiers in Cell and Molecular Biology", October 1995, Warsaw, p. 30.
  220. Coupling of the c-Cb1 proto-oncogene product to ErbB-1/EGF receptor but not to other ErbB proteins. G. Levkowitz, L.N. Klapper, E. Tzahar, A. Freywald, M. Sela and Y. Yarden, Abstr. First Congress of FISEB, October 1995, Eilat, p. 95.
  221. Vicinal side chain interaction in Tyr-Glu peptide antigens and its role in T cell recognition. K.A. Muszkat, M. Sela, V. Pregerzon, A. Jakob and L. Konstantinovskii, Abstr. First Congress of FISEB, October 1995, Eilat, p. 69.
  222. Immune reactivity of seronegative myasthenia gravis patients to myasthenogenic peptides (epitopes) of the human acetylcholine receptor. A. Karni, E. Zisman, Y. Katz-Levy, M. Paz, M. Dayan, Z. Argove, C. Brautbar, O. Abramsky, M. Sela and E. Mozes, Abstr. Cong. Amer. Neurol.
  223. Copolymer 1 induces suppressor T-cells of the TH2 type. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Abstr. Sixth Meet. Eur. Neurol. Soc., Hague, June 1996.
  224. Suppressor T cells induced by copolymer 1 secrete TH2 cytokines. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Abstr. 5th Internat. Expert Forum on Immunotherapy and Gene Therapy, Jerusalem June 1996.
  225. GLAT: a synthetic random copolymer prevents murine graft-vs-host disease. R. Aharoni, P.G. Schlegel, D. Teitelbaum, R. Arnon, M. Sela and N.J. Cha. Abstr. 26th Congress of Israel Immunol. Soc., May 1996.
  226. Copolymer 1 induces suppressor-T cells of the TH2 type. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Abstr. 26th Congress of Israel Immunol. Soc., May 1996, poster only.
  227. Inhibition of autoimmune manifestations related to myasthenia gravis by a peptide analog. Y. Katz-Levy, M. Paas-Rosner, M. Dayan, S.L. Kirshner, M. Sela and E. Mozes, Abstr. 26th Congress of Israel Immunol. Soc., May 1996, p. 43.
  228. Molecular studies of the therapeutic potential of monoclonal antibodies to the ErbB-2 receptor, L.N. Klapper, E. Hurwitz, Y. Yarden and M. Sela, Abstr. 26th Congress of Israel Immunol. Soc., May 1996, p. 64.
  229. Copolymer 1 induces suppressor T cells of the Th2 type. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, 12th ECTRIM Congress, Copenhagen, September 1996.
  230. Antibodies to Copolymer 1 do not interfere with its therapeutic effect. D. Teitelbaum, T. Brenner, M. Sela and R. Arnon, 12th ECTRIM Congress, Copenhagen, September 1996.
  231. Immunomodulation of EAE by T suppressor cells of the Th2 subtype induced by Copolymer 1. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, "Pathogenesis and Immunotherapy of Autoimmune Diseases", October 1996, Milano.
  232. Towards synthetic vaccines against autoimmune disease: multiple sclerosis and myasthenia gravis. M. Sela, Abstracts 25th Meet., Romanian Society for Immunology, p. 70, paper S16, Bucharest, September 1996.
  233. Cop. 1 - peptide approach to the treatment of multiple sclerosis. D. Teitelbaum, M. Sela and R. Arnon, Abstr., Austria.
  234. Bystander suppression of proteolipid protein induced experimental autoimmune encephalomyelitis by Th2 suppressor cells specific to copolymer 1. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Rhodes, EMS.
  235. From mouse to man - the development of a peptide-based approach for the prevention of graft-versus-host disease. P.G. Schlegel, R. Aharoni, D. Teitelbaum, R. Arnon, M. Sela and N.J. Chao, 4th Intl. Symp. Clinical Immunol., Amsterdam.
  236. Mechanism and specificity of GVHD modulation by the synthetic copolymer GLAT R. Aharoni, P.G. Schlegel, D. Teitelbaum, O.R. Karpov, R. Arnon, M. Sela, N. Chao, Abst. 13th Europ. Immun. Meeting, Amsterdam, June 1997.
  237. Bystander suppression of experimental autoimmune encephalomyelitis by TH2 suppressor cells specific to Copolymer 1. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Abst. 13th Europ. Imm. Meeting, Amsterdam, June 1997
  238. Clustering of MHC Class II molecules on antigen presenting cells following binding of Copolymer 1 and myelin basic protein. D. Teitelbaum, M. Fridkis-Hareli, I. Pecht, R. Arnon and M. Sela, Abstr. 13th Europ. Immunol. Meeting, Amsterdam, June 1997.
  239. Copolymer 1 inhibits the response to myelin basic protein p84-102 by T cell receptor antagonism in addition to MHC blocking. R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela. XVI Cong. Neurology, Buenos Aires, Sept. 1997, J. Neurol. Sci. 150, Suppl. p. S115.
  240. Suppression of experimental allergic encephalomyelitis by oral administration of copolymer 1 (Copaxone). D. Teitelbaum, R. Aharoni, M. Sela and R. Arnon, Abst. XVI Cong. Neurology, Buenos Aires, Sept. 1997, J. Neurol. Sci. 150, Suppl. p. S188.
  241. A subclass of tumor-inhibitory monoclonal antibodies to ErbB2/HER2 blocks crosstalk with growth factor receptors. L.N. Klapper, N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, Y. Yarden and M. Sela, Abstr. 27th Meet. Israel Immunol. Soc., Ramat-Gan, May 1997, p. 57.
  242. Synthetic peptide vaccines in autoimmune diseases. M. Sela, Abstr. Meet. on "Active Immunization for Autoimmune and Infectious Diseases", Annecy, May 1997, p. 47.
  243. The concept of specific immune treatment against autoimmune diseases. M. Sela, Abstr. 1st Intl. Symp. on Molecular Medicine, October 1998, Hersonissos, Crete, INtl. J. Molecular Medicine 2, Suppl. 1, p. 57, 1998
  244. Induction of Th2 suppressor T cells by daily subcutaneous injections of copolymer 1 (Copaxone). R. Aharoni, D. Teitelbaum M. Sela and R. Arnon, Abstr. Fifth Congr. Intl. Soc. Neuroimmunology, Montreal, Canada, August 1998, J. Neuroimmunol. Special Issue, p. 86.
  245. Immunomodulation of experimental allergic encephalomyelitis by oral adminstration of Copolymer 1 (Copaxone). D. Teitelbaum, R. Arnon and M. Sela, Abstr. Fifth Congr. Intl. Soc. Neuroimmunology, Montreal, Canada, August 1998, Neuroimmunol., Special Issue, p. 85.
  246. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity but not tyrosine phosphorylation induced by two myasthenogenic T cell epitopes. A. Faber-Elmann, M. Paas-Rozner, M. Sela and E. Mozes, Abstr. IXth Intl. Congr. Neuromuscular Diseases, Adelaide (Australia), Sept. 1998.
  247. The ErbB-2/HER2 oncogene: understanding its significance by using therapeutic tools. L.N. Klapper, N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, E. Tzahar, Y. Yarden and M. Sela, Abstr. 2nd Congr. FISEB, Eilat, December 1998. p. 188.
  248. Immunological changes associated with Copaxone (glatiramer-acetate) therapy in multiple sclerosis. R. Riven-Kreitman, R. Aharoni, D. Teitelabum, T. Brenner, S. Shapiro, N. Lahat, A. Miller, R. Arnon and M. Sela, Meeting on "Use of Imaging and Other Monitoring "Measurements in Multiple Sclerosis Treatment Strategies", Santa Fe, New Mexico, November 1998.
  249. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. D. Teitelbaum, R. Arnon and M. Sela, Abstr. 2nd Congr. FISEB, Eilat, December 1998,p. 110.
  250. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to MHC blocking. R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela, Abstr. 2nd Cong. FISEB, Eilat, December 1998, p. 215.
  251. From synthetic antigens to specific vaccines against autoimmune diseases. M. Sela, J. Autoimmunity, Supplement, Abstr. 2nd Intl. Congress on Autoimmunity, March 1999, p. 6.
  252. The crucial role of amino acids and their polymers in our understanding of immunological phenomena, and the different roles that D-amino acids are playing. M. Sela, 6th Intl. Congr. Amino Acids, Bonn, August 1999, Amino Acids, 17, 128 (1999)
  253. Specific TH2 cells are present in the central nervous system of mice protected against EAE by Copolymer 1. R. Aharoni, D.Teitelbaum, M. Sela and R. Arnon. Cong. Europ. Neurol. Soc. Jerusalem, June 2000, J. Neurology, p III/58.
  254. Isolation and characterization of copolymer 1 specific TH2 cells from CNS of mice protected against EAE. R. Aharoni, D. Teitelbaum, M. Sela an d R. Arnon, Immunology, 2000, Seattle.
  255. A dual analog of two myasthenogenic peptides ameliorates clinical experimental autoimmune myasthenia gravis in mice. M. Paas-Rozner, M. Dayan, I. Wirguin, M. Sela and E. Mozes, Cong. Israel Immunol. Soc.
  256. Specific TH2 cells are present in the central nervous system of mice protected against EAE by Copolymer 1. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Abstr. Eur. Fed. Neurol. Societies, Denmark, November 2000.
  257. Vaccination with a safe MBP-crossreactive peptide as a possible treatment for CNS injuries. J. Kipnis, E. Yoles, M. Sela, I.R. Cohen and M. Schwartz, Abstr. Congr. Neurosciences, New Orleans, January 2001.
  258. Legacy of Louis Pasteur for Immunology in the 21st Century. Symposium on "New Challenges for Research in Biology. "Pasteurian Missions for the 21st Century", Arc-et-Senans 12-14 Sept. 2000, p. 7.
  259. Copolymer 1 specific T-cells from the CNS and the periphery of mice protected against EAE exhibit Th2 profile when activated by CNS antigen presenting cells. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, World Cong. Neurology, London, June 2001.
  260. A dual altered peptide ligand (APL) down regulates myasthenogenic autoimmune associated responses via immunomodulation of cytokines. N. Rozner-Paas, M. Dayan, M. Sela and E. Mozes, Abstr. 30th Cong. Israel Assoc. Immunol., p. 44 (2001).
  261. Copolymer 1 specific T-cells from the CNS and the periphery exhibit Th2 profile when activated by CNS antigen presenting cells. R. Aharoni, D. Teitelbaum, M. Sela and R. Arnon, Congr. Europ. Neurol. Soc. Paris, April 2001, J. Neurology, P304, II, 87.

 Patents

  1. Cleavage of Human Gamma Globulin by Means of Cyanogen Bromide.
    M. Sela, R. Arnon and M. Lahav.
    U.S. Patent 3,466,368 (1969); Israel Patent 27713 (1970).
  2. Protein-Bacteriophage Conjugates.
    J. Haimovich and M. Sela.
    Belgian Patent 744,478 (1970); South African Patent 70/0115; Italian Patent 892501 (1971); French Patent 70/01597 (1972); U.S. Patent 3,717,705 (1973); Israel Patent 33718 (1973); United Kingdom Patent 1303802 (1973); Canadian Patent 956237 (1974); Australian Patent 445921 (1974), Swiss Patent 546405 (1974).
  3. Pronase Purification.
    S. Shaltiel and M. Sela.
    U.K. Patent 1,224,181 (1971).
  4. Therapeutic Copolymer.
    D. Teitelbaum, A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela.
    Israel 36670 (1974); U.S. Patent 3849550 (1974); Canadian Patent 1,006,508 (1977); German Patent DE 2,217,817 C2.
  5. Pharmaceutically Active Compositions.
    M. Sela, R. Arnon, E. Hurwitz, R. Maron and R. Levy.
    United Kingdom Patent 1446536 (1976); South African Patent 75/1264.
  6. Conjugates of Anti-Cancer Drugs with Antibodies.
    M. Sela, R. Arnon, E. Hurwitz, R. Maron and R. Levy.
    Canadian Patent 1050012, March 1979.
  7. Novel Synthetic Undecapeptide and Clinical Assay.
    M. Sela, R. Arnon and S. Chaitchik. vU.S. Patent 4075194 (1978).
  8. Fab Dimers Bound to Anti-Cancer Drugs.
    M. Sela, R. Arnon, R. Maron and E. Hurwitz.
    South African Patent 79/2966.
  9. Immunologic Chemotherapeutic Agents Comprising Antigen Binding Dimers Covalently Bound to Drugs.
    M. Sela, R. Arnon, R. Maron and E. Hurwitz.
    U.S. Patent 4093607. Swedish Patent 7605942-7.
  10. Anti-Cancer Drug Comprising Platinum Complexes.
    R. Arnon, E. Hurwitz, R. Kashi, M. Wilchek, M. Sela and B. Schechter.
  11. Vaccines.
    M. Sela, R. Arnon and Ch. O. Jacob.
    United Kingdom Patent 2145419 (1987).
  12. Synthetic Cholera Vaccines.
    U.S. Patent 4,751,064.
  13. Vaccin Synthetique contre le Cholera.
    French Patent 84 13113 (1988).
  14. Synthetic Peptides and Pharmaceutical Compositions Comprising Them (for the Treatment of Myasthenia Gravis).
    Edna Mozes and Michael Sela.
    E. P. Patent No. 0 832 127, Serial No. 9691 6286.6
  15. Method for Prognosticating Response to Cancer Therapy Using Monoclonal Antibodies. Yosef Yarden and Michael Sela.
  16. Copolymer 1; Improvements in Compositions of Copolymers.
    E. Konfino, M. Sela, D. Teitelbaum and R. Arnon.
    U.S. Patent No. 5,800,808
  17. Pharmaceutical Compositions Comprising Synthetic Peptide Copolymer for Prevention of GVHD.
    R. Aharoni, R. Arnon, N.J. Chao, P.G. Schlegel, M. Sela and D. Teitelbaum.
    U.S. Patent No. 5, 858, 964.
  18. Copolymer-1, Improvements in Compositions of Copolymer.
    E. Konfino, M. Sela, D. Teitelbaum and R. Arnon.
    U.S. Patent No. 5, 981, 589.
  19. Treatment of Multiple Sclerosis Through Ingestion or Inhalation of Copolymer 1.
    R. Arnon, M. Sela, D. Teitelbaum, A. Gilbert, M. Linenberg, R. Riven-Kreitmann.
    U.S. Patent No. 6, 214, 791 (2001).